$143.44
+4.52 (+3.25%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GILD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 469 interventional · 31 observational · 340 with posted results
Held by 23 tracked-famous managers (Dodge & Cox, CITADEL ADVISORS LLC, Holocene Advisors, LP, Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., +18 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 7 sells · government filings 180d: 2 congress / 6 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsNCT06337032Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the StudyNon-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), E/C/F/TAF, E/C/F/TAF (Low Dose), Cobicistat (High Dose), Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, Lopinavir Boosted with ritonavir (LPV/r) | HIV-1-infection | 350 | Mar 2034 | ≤ 2,781 d | 2026-06-10 |
| Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentNCT07708727Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmRandomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF | HIV-1-infection | 700 | Oct 2030 | ≤ 1,534 d | 2026-08-14 |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisNCT06051617Event Free Survival (EFS)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Seladelpar, Placebo | Primary Biliary Cholangitis | 318 | Aug 2030 | ≤ 1,473 d | 2026-08-11 |
| Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1NCT06532656PK Parameter: Cmax of BIC and LEN at Steady StateOpen-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: Lenacapavir, BIC/LEN FDC | HIV-1-infection | 75 | Jul 2030 | ≤ 1,442 d | 2026-06-04 |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadNCT03547973Overall Response Rate (ORR) Based on Central Review by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria (Cohorts 1 to 4 and 6)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin | Metastatic Urothelial Cancer | 827 | Apr 2030 | ≤ 1,350 d | 2026-03-16 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusNCT07096193Phase 1 and 2: Percentage of Participants With Treatment-emergent Adverse EventsNon-randomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Drug: GS-4321, GS-4321 Placebo, GS-4321 | Chronic Hepatitis Delta | 200 | Jan 2030 | ≤ 1,261 d | 2026-07-30 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasNCT07546812Objective Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Denikitug, Nivolumab, Ramucirumab, Paclitaxel | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 120 | Jan 2030 | ≤ 1,261 d | 2026-07-10 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available) | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 695 | Oct 2029 | ≤ 1,169 d | 2026-08-12 |
| Study of Novel Treatment Combinations in Patients With Lung CancerNCT05633667Substudies 01 and 02: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab | Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer | 192 | Sep 2029 | ≤ 1,138 d | 2026-06-01 |
| A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsNCT07703878Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: GS-1206 | Solid Tumor | 302 | Sep 2029 | ≤ 1,138 d | 2026-08-10 |
| Study of GS-0415 and How It Works in People With HIVNCT07719491Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)Randomized · Single-masked · Treatment | Phase 1 | Not yet recruiting | Drug: GS-0415, GS-0415 Placebo | HIV -1 Infection | 112 | Aug 2029 | ≤ 1,108 d | 2026-07-22 |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)NCT06486441Progression-Free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel | Endometrial Cancer | 640 | Jun 2029 | ≤ 1,046 d | 2026-07-29 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyNCT07682961Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine | HIV Infections | 590 | Mar 2029 | ≤ 955 d | 2026-08-14 |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensNCT07683000Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, SBR | HIV-1-infection | 590 | Mar 2029 | ≤ 955 d | 2026-07-30 |
| Study of GS-2426 in Participants With Advanced Solid TumorsNCT07601243Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: GS-2426 | Advanced Solid Tumors | 174 | Jan 2029 | ≤ 896 d | 2026-08-03 |
| Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsNCT05007782Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Part A and CNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Denikitug, Zimberelimab | Advanced Solid Tumor | 416 | Dec 2028 | ≤ 865 d | 2025-12-29 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerNCT07527858Objective Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil | Advanced Microsatellite Stable Colorectal Cancer | 170 | Dec 2028 | ≤ 865 d | 2026-07-28 |
| Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)NCT03301506Treatment emergent adverse events (TEAEs) (National Cancer Institute {NCI} Common Terminology Criteria for Adverse Events {CTCAE} Version 5.0), biochemistry and hematology resultsNon-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule | Primary Biliary Cirrhosis | 340 | Nov 2028 | ≤ 834 d | 2026-05-04 |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsNCT06167317The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose EscalationNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: GS-0201, Sacituzumab Govitecan | Advanced Solid Tumors | 278 | Sep 2028 | ≤ 773 d | 2026-08-13 |
| Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716Plasma LEN Ctrough at Week 52Non-randomized · Open-label · Prevention | Phase 3 | Active, not recruiting | Drug: Lenacapavir Injection, Lenacapavir Tablet | HIV Pre-exposure Prophylaxis | 339 | Sep 2028 | ≤ 773 d | 2026-06-22 |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin | Triple Negative Breast Cancer, PD-L1 Negative | 623 | Jul 2028 | ≤ 712 d | 2026-04-06 |
| Study of Bulevirtide in Participants With Chronic Hepatitis D InfectionNCT05718700observationalExposure-adjusted Incidence of Participants With Liver-related Event: Hepatic Decompensation, Hepatocellular Carcinoma (HCC), Liver Transplantation, and Liver-related Death | — | Active, not recruiting | Drug: Bulevirtide | Chronic Hepatitis D Infection | 170 | Jul 2028 | ≤ 712 d | 2025-11-17 |
| Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237Overall Survival (OS) in Participants With Positive Programmed Cell Death-Ligand 1 (PD-L1) Expression (≥1%Tumor Cells) and in all Randomized Participants.Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed | Non-small Cell Lung Cancer | 1,021 | Jun 2028 | ≤ 681 d | 2026-01-30 |
| Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid TumorsNCT06532565Parts A and B: Percentage of Participants with Adverse Events and Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: GS-2121, Zimberelimab | Advanced Solid Tumors | 154 | Jun 2028 | ≤ 681 d | 2026-04-21 |
| A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerNCT06926920Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Sacituzumab Govitecan-hziy (SG) | Triple Negative Breast Cancer | 100 | Jun 2028 | ≤ 681 d | 2026-01-30 |
| Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsNCT07128303Percentage of Participants With Adverse Events (AEs) and Serous Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: GS-5319, Carboplatin, Pemetrexed, Pembrolizumab | Advanced Solid Tumor | 476 | May 2028 | ≤ 651 d | 2026-08-19 |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine | Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer | 654 | Apr 2028 | ≤ 620 d | 2025-10-03 |
| Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV PreventionNCT07473778observationalProportion of Participants with LEN PrEP Persistence at Week 52 | — | Recruiting | Drug: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet | HIV Infections | 3,000 | Apr 2028 | ≤ 620 d | 2026-08-19 |
| Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVNCT07055451Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAs) Though Week 8 After Neonate BirthNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: B/F/TAF | HIV-1-infection | 16 | Mar 2028 | ≤ 590 d | 2026-06-18 |
| Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedNCT06544733Phase 2: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmRandomized · Double-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC | HIV-1-Infection | 675 | Jan 2028 | ≤ 530 d | 2026-04-17 |
| Study With Various Immunotherapy Treatments in Participants With Lung CancerNCT05676931Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet | Advanced Non-Small Cell Lung Cancer | 400 | Dec 2027 | ≤ 499 d | 2026-06-01 |
| A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1NCT07645287Part A: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF | HIV-1-infection | 175 | Aug 2027 | ≤ 377 d | 2026-08-06 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654Invasive Disease-free Survival (iDFS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine | Triple Negative Breast Cancer | 1,514 | Jun 2027 | ≤ 315 d | 2026-07-15 |
| Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer | 135 | May 2027 | ≤ 285 d | 2026-07-10 |
| Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and ChildrenNCT06749054Pharmacokinetic (PK) Parameter: Ctrough, W26 of Lenacapavir (LEN)Open-label · Treatment | Phase 2 | Recruiting | Drug: Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR) | HIV-1-infection | 12 | Mar 2027 | ≤ 224 d | 2026-04-24 |
| Study of GS-0151 in Participants With Rheumatoid ArthritisNCT06902519Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: GS-0151, Placebo | Rheumatoid Arthritis | 75 | Mar 2027 | ≤ 224 d | 2026-06-09 |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin | Triple Negative Breast Cancer, PD-L1 Positive | 443 | Feb 2027 | ≤ 193 d | 2025-09-18 |
| Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisNCT06029972Proportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at Week 12Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: Tilpisertib Fosmecarbil, Placebo | Ulcerative Colitis | 176 | Jan 2027 | ≤ 165 d | 2026-02-11 |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentNCT04617522Percentage of Participants experiencing Treatment Emergent Adverse Events (TEAEs) and Serious AEsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Sacituzumab Govitecan-hziy | Advanced or Metastatic Solid Tumor, Liver Failure | 30 | Dec 2026 | ≤ 134 d | 2026-06-02 |
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product, Gemcitabine Injection, Vinorelbine injection | Metastatic Breast Cancer | 331 | Dec 2026 | ≤ 134 d | 2026-02-09 |
| Study of GS-9911 With or Without Antibody Treatment for Adults With Solid TumorsNCT06082960Percentage of Participants With Treatment-emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: GS-9911, Zimberelimab | Solid Tumors | 45 | Dec 2026 | ≤ 134 d | 2026-04-16 |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)NCT06562907Single-Dose PK Parameter AUCinf of GS-4571Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: GS-4571, Placebo, Omeprazole | Weight Management | 134 | Nov 2026 | ≤ 103 d | 2026-06-22 |
| Study of Sacituzumab Govitecan in Patients With Solid TumorNCT05119907Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator AssessmentNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Solid Tumor | 53 | Oct 2026 | ≤ 73 d | 2025-11-17 |
| Study of GS-4528 in Adults With Solid TumorsNCT05840224Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: GS-4528 · Drug: Zimberelimab | Solid Tumor | 182 | Oct 2026 | ≤ 73 d | 2026-07-27 |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionNCT02932150Incidence of Treatment-Emergent Serious Adverse Events (SAEs) at Week 24Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: TAF, Placebo | Chronic Hepatitis B | 150 | Sep 2026 | ≤ 42 d | 2026-06-18 |
| Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin | Non-small Cell Lung Cancer | 193 | Sep 2026 | ≤ 42 d | 2026-02-11 |
| Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565Objective response rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin | Head and Neck Squamous Cell Carcinoma | 100 | Aug 2026 | ≤ 12 d | 2026-03-02 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN): LEN Plasma concentration at the End of the Dosing Interval (Week 26)Randomized · Open-label · Prevention | Phase 2 | Active, not recruiting | Drug: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Pre-Exposure Prophylaxis of HIV Infection | 181 | 2026-07-27actual | — | 2026-08-13 |
| Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN) at the End of Week 26Randomized · Open-label · Prevention | Phase 2 | Active, not recruiting | Drug: Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Pre-Exposure Prophylaxis of HIV Infection | 253 | 2026-07-22actual | — | 2026-08-17 |
| Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312Percentage of Participants with LEN and F/TDF Persistence through 52 WeeksRandomized · Open-label · Prevention | Phase 2 | Active, not recruiting | Drug: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Pre-Exposure Prophylaxis of HIV Infection | 268 | 2026-05-28actual | — | 2026-06-15 |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1NCT06630299Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: ISL/LEN, Antiretroviral Combinations | HIV-1-Infection | 600 | 2026-04-23actual | — | 2026-05-29 |
| Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1NCT06630286Proportion of Participants with HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-Defined Snapshot AlgorithmRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN | HIV-1-infection | 609 | 2026-04-17actual | — | 2026-04-30 |
| Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative ColitisNCT06290934Proportion of Participants Achieving Clinical Response at Week 12Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: emvistegrast, Placebo-to-match emvistegrast | Ulcerative Colitis | 228 | 2026-03-04actual | — | 2026-04-09 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyNCT06333808Proportion of Participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the US FDA-defined Snapshot AlgorithmRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN | HIV-1-infection | 577 | 2025-10-27actual | — | 2026-06-15 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenNCT05502341Phase 2: Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot AlgorithmRandomized · Open-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen | HIV-1-infection | 689 | 2025-09-29actual | — | 2026-08-10 |
| Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVNCT02016924Pharmacokinetic (PK) Parameter: AUCtau of ATV, DRV, TAF, and TFVNon-randomized · Open-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | 133 | 2025-06-13actual | — | 2026-04-21 |
| Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1NCT02881320PK Parameter: AUCtau of BictegravirNon-randomized · Open-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS) | HIV-1 Infection | 177 | 2025-03-24actual | — | 2026-03-24 |
| Study of Sacituzumab Govitecan in Participants With Metastatic Solid TumorsNCT03964727results2026-01-30Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's AssessmentNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Metastatic Solid Tumor | 227 | 2025-01-15actual | — | 2026-04-28 |
| Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV InfectionNCT04925752results2025-09-17Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)Randomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only) | Pre-Exposure Prophylaxis of HIV Infection | 3,292 | 2024-08-21actual | — | 2025-12-23 |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionNCT05729568results2025-07-15Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot AlgorithmRandomized · Open-label · TreatmentStudy Protocol: Protocol Amendment 3 ↗ · Study Protocol: Protocol Amendment 4 ↗ · Statistical Analysis Plan: Week 26 Analysis ↗ · Statistical Analysis Plan: Week 52 Analysis ↗ | Phase 2 | Active, not recruiting | Drug: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy | HIV-1 Infection | 83 | 2024-07-02actual | — | 2026-04-27 |
| Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionNCT04994509results2025-06-19Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)Randomized · Double-masked · PreventionStudy Protocol: Protocol Amendment 4 ↗ · Study Protocol: Protocol Amendment 5 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF, F/TDF, Placebo SC LEN, PTM Oral LEN, PTM F/TAF, PTM F/TDF | Pre-Exposure Prophylaxis of HIV Infection | 5,368 | 2024-05-27actual | — | 2026-08-07 |
| Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996results2025-01-14Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot AlgorithmRandomized · Open-label · TreatmentStudy Protocol: Protocol Amendment 6 ↗ · Study Protocol: Protocol Amendment 5 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: ISL, LEN, B/F/TAF, ISL/LEN FDC | HIV-1 Infection | 142 | 2023-12-19actual | — | 2026-02-04 |
| Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT05089734results2025-01-14Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: Sacituzumab Govitecan-hziy (SG) · Drug: Docetaxel | Non-Small Cell Lung Cancer | 603 | 2023-11-29actual | — | 2026-05-07 |
| Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsNCT04454437Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Independent Review Committee (IRC)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Metastatic Triple-negative Breast Cancer | 80 | 2021-08-06actual | — | 2026-02-02 |
| Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistanceNCT04150068results2021-10-20Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol: Amendment 2 ↗ · Study Protocol: Amendment 5 ↗ · Statistical Analysis Plan: Primary Efficacy Endpoint Analysis ↗ · Statistical Analysis Plan: Week 26 Interim Analysis ↗ · Statistical Analysis Plan: Year 2 and 3 analysis ↗ | Phase 2/3 | Active, not recruiting | Drug: Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR) | HIV-1-infection | 72 | 2020-10-05actual | — | 2026-03-13 |
| Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 InfectionNCT02842086results2020-03-17Incidence of HIV-1 Infection Per 100 Person Years (PY)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo | Pre-Exposure Prophylaxis of HIV-1 Infection | 5,399 | 2019-01-31actual | — | 2026-05-05 |
| Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B InfectionNCT01651403results2018-09-19Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)Randomized · Triple-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Statistical Analysis Plan: Week 48 Analysis ↗ · Statistical Analysis Plan: Week 192 Analysis ↗ | Phase 3 | Active, not recruiting | Drug: Tenofovir DF, TDF Placebo | Chronic Hepatitis B | 90 | 2017-08-07actual | — | 2026-01-30 |
| Study of GS-0272 in Participants With Rheumatoid ArthritisNCT06031415Percentage of Participants Experiencing Adverse Events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to lack of efficacy. | Drug: GS-0272, Placebo | Rheumatoid Arthritis | 55 | 2026-05-11actual | — | 2026-05-27 |
| Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)NCT06060665Percentage of Participants Response defined as Alkaline phosphatase (ALP) ≤ 1.0× Upper Limit of Normal (ULN) AND ≥ 15% Decrease in ALP at Week 52.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Seladelpar 10 mg, Placebo | Primary Biliary Cholangitis | 96 | 2026-05-06actual | — | 2026-06-04 |
| Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedNCT06613685Phase 2: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmRandomized · Double-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC | HIV-1-infection | 73 | 2026-03-16actual | — | 2026-04-15 |
| Study of GS-3242 in Participants With HIV-1; Substudy-05NCT07001319Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo DataOpen-label · Treatment | Phase 1 | Completed | Drug: GS-3242, BVY, Standard of Care | HIV-1-infection | 27 | 2026-03-03actual | — | 2026-05-11 |
| Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus DiseaseNCT06682234Percentage of Participants Experiencing Serious Adverse Events (SAEs)Open-label · Prevention | Phase 2 | Withdrawnsponsor's stated reason: The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants. | Drug: obeldesivir | Filovirus Disease, Postexposure Prophylaxis for Filovirus Disease | 0 | Dec 2025 | — | 2026-03-20 |
| Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)NCT05629208Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 12Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Edecesertib, Edecesertib Placebo | Cutaneous Lupus Erythematosus (CLE) | 20 | 2025-12-17actual | — | 2026-02-17 |
| Study of GS-1219 in Participants With HIV-1NCT07115368Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo DataOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: GS-1219, BVY, Standard of Care | HIV-1-infection | 4 | 2025-09-19actual | — | 2025-10-21 |
| A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in SpainNCT06683482observationalNumber of Participants With Responses to the Open-ended questionnaires | — | Completed | Other: No intervention | Breast Cancer | 41 | 2025-07-28actual | — | 2025-08-06 |
| Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadNCT04527991results2026-06-02Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine | Locally Advanced or Metastatic Unresectable Urothelial Cancer | 711 | 2025-07-04actual | — | 2026-06-02 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid MalignanciesNCT05006794Percentage of Patients Experiencing Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to terminate | Drug: zamzetoclax, Docetaxel, sacituzumab govitecan-hziy | Solid Malignancies | 37 | 2025-06-16actual | — | 2026-07-17 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) InfectionNCT06585150results2026-06-30Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated by Sponsor; the decision was not due to any safety findings. | Drug: Obeldesivir, Obeldesivir Placebo | RSV Infection | 150 | 2025-05-08actual | — | 2026-06-30 |
| Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) InfectionNCT06784973results2026-06-08Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated by Sponsor; the decision was not due to any safety findings. | Drug: Obeldesivir, Obeldesivir Placebo | RSV Infection | 4 | 2025-04-16actual | — | 2026-06-08 |
| An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)NCT04950764results2026-05-04Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Seladelpar | Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment | 24 | 2025-02-24actual | — | 2026-05-04 |
| Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)NCT06104306results2026-02-11Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: B/F/TAF | HIV-1-infection | 33 | 2025-01-29actual | — | 2026-02-11 |
| Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected WomenNCT05281510results2026-01-16Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Vesatolimod · Biological: VRC07523LS, CAP256V2LS | HIV-1-infection | 20 | 2025-01-16actual | — | 2026-01-16 |
| Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis BNCT05770895results2026-01-23Percentage of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: GS-2829, GS-6779, Placebo | Chronic Hepatitis B | 83 | 2025-01-15actual | — | 2026-01-23 |
| Study of Bulevirtide in Participants Who Have Normal or Impaired Liver FunctionNCT05765344results2026-01-26Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Bulevirtide, Bulevirtide | Hepatic Impairment, Healthy | 74 | 2025-01-10actual | — | 2026-01-26 |
| Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)NCT04971785results2025-11-26Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo GroupsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR | Nonalcoholic Steatohepatitis | 457 | 2024-11-12actual | — | 2025-11-26 |
| Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziyNCT04319198results2025-09-30Percentage of Participants Experiencing Any Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Sacituzumab Govitecan-hiy | Metastatic Solid Tumors | 25 | 2024-10-18actual | — | 2025-09-30 |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04958785results2025-10-03Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy | Triple-Negative Breast Cancer | 92 | 2024-10-08actual | — | 2025-11-04 |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaNCT04854499results2025-11-19Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate study | Drug: Magrolimab, Pembrolizumab, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab | Head and Neck Squamous Cell Carcinoma | 193 | 2024-10-02actual | — | 2025-11-19 |
| Study of Magrolimab in Patients With Solid TumorsNCT04827576results2025-05-08Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate study | Drug: Magrolimab, Docetaxel | Solid Tumor | 106 | 2024-10-01actual | — | 2025-05-08 |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesNCT02457598results2025-06-17Percentage of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated. | Drug: Tirabrutinib, Idelalisib, Entospletinib, Obinutuzumab | B-cell Malignancies | 203 | 2024-09-25actual | — | 2025-06-17 |
| A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal FunctionNCT05760300results2025-09-18Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtauNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Bulevirtide (BLV) | Chronic Hepatitis D Infection | 41 | 2024-07-18actual | — | 2025-09-18 |
| Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)NCT05330429results2025-07-01Safety Run-in Cohort: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate study | Drug: Magrolimab, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin | Metastatic Colorectal Cancer | 77 | 2024-06-26actual | — | 2025-07-01 |
| Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir AlafenamideNCT03580668observationalProportion of Participants with HIV-1 RNA Suppression (HIV RNA < 50 copies/mL) at 12 Months after initiating or switching to B/F/TAF | — | Completed | Drug: B/F/TAF | HIV-1-infection | 201 | 2024-06-03actual | — | 2024-06-18 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaNCT04892446results2025-05-02Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program. | Drug: Magrolimab, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib | Multiple Myeloma | 36 | 2024-04-25actual | — | 2025-05-02 |
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaNCT05079230results2025-04-04Overall Survival (OS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study was terminated due to futility | Drug: Magrolimab, Venetoclax, Azacitidine, Placebo | Acute Myeloid Leukemia | 378 | 2024-04-11actual | — | 2025-04-04 |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNCT02953509results2025-05-29Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment CombinationNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study terminated early due to the magrolimab program discontinuation. | Drug: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol | Non Hodgkin Lymphoma | 178 | 2024-03-25actual | — | 2025-05-29 |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedNCT04778397results2025-02-05Overall Survival (OS) in Participants Appropriate for Non-intensive TherapyRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study discontinued due to futility. | Drug: Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops | Acute Myeloid Leukemia | 258 | 2024-03-25actual | — | 2025-02-05 |
| Study of Magrolimab Combinations in Participants With Myeloid MalignanciesNCT04778410results2025-03-20Complete Remission (CR) Rate (Cohorts 1 and 2)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate the study. | Drug: Magrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486 | Myeloid Malignancies | 54 | 2024-03-04actual | — | 2025-03-20 |
| Study of Obeldesivir in Children and Adolescents With COVID-19NCT05996744results2025-02-03Plasma Concentration of GS-441524, Metabolite of Obeldesivir (ODV)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Study was terminated by Sponsor; the decision was not due to any safety findings. | Drug: Obeldesivir | COVID-19 | 3 | 2024-02-23actual | — | 2025-02-03 |
| Study of Novel Antiretrovirals in Participants With HIV-1NCT05585307results2025-05-08Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo DataNon-randomized · Open-label · TreatmentStudy Protocol: Substudy 01 Protocol Amendment 01 ↗ · Study Protocol: Substudy 02 Protocol Amendment 02 ↗ · Study Protocol: Substudy 03 Protocol Amendment 01 ↗ · Statistical Analysis Plan: Substudy 01 Statistical Analysis Plan ↗ · Statistical Analysis Plan: Substudy 02 Statistical Analysis Plan ↗ · Statistical Analysis Plan: Substudy 03 Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03) | HIV-1-infection | 49 | 2024-02-17actual | — | 2025-05-08 |
| Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)NCT04891770results2025-07-24Percentage of Participants Who Achieved Functional CureRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tenofovir Alafenamide, VIR-2218, Nivolumab, Selgantolimod | Chronic Hepatitis B | 103 | 2024-01-23actual | — | 2025-07-24 |
| Study of Obeldesivir in Nonhospitalized Participants With COVID-19NCT05715528results2024-12-24Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Obeldesivir, Obeldesivir Placebo | COVID-19 | 2,011 | 2023-11-28actual | — | 2024-12-24 |
| Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe IllnessNCT05603143results2024-12-20Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization or All-Cause Death by Day 29Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events. | Drug: Obeldesivir, Obeldesivir Placebo | COVID-19 | 468 | 2023-11-07actual | — | 2024-12-20 |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerNCT03901339results2024-10-21Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) AssessmentRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine | Metastatic Breast Cancer | 543 | 2023-10-20actual | — | 2024-10-21 |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)NCT04313881results2024-03-21Percentage of Participants With Complete Remission (CR)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: First Interim Analyses ↗ · Statistical Analysis Plan: Second Interim and Final Analyses ↗ | Phase 3 | Terminatedsponsor's stated reason: Study discontinued due to futility based on a planned analysis | Drug: Magrolimab, Azacitidine, Placebo | Myelodysplastic Syndromes | 539 | 2023-09-13actual | — | 2024-06-27 |
| Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological MalignanciesNCT03248479results2025-01-17Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial. | Drug: Magrolimab, Azacitidine | Hematological Malignancies | 258 | 2023-09-05actual | — | 2025-01-17 |
| RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)NCT04620733results2024-07-25Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Seladelpar 10 mg, Placebo, Seladelpar 5 mg | Primary Biliary Cholangitis | 193 | 2023-08-11actual | — | 2024-09-05 |
| Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus LevelsNCT05458102results2024-12-03Pharmacokinetic (PK) Parameter : AUClast of Vesatolimod (VES)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns. | Drug: Vesatolimod, Cobicistat, Voriconazole, Rifabutin | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | 18 | 2023-05-01actual | — | 2024-12-03 |
| Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) TreatmentNCT05165771Change From Baseline in Disease Activity Score (DAS) Based on 28 Joints Using C-reactive Protein (CRP) DAS28 (CRP) at Week 12Randomized · Double-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor decision to withdraw study. | Drug: GS-5718, GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg, Placebo to match Tofacitinib | Rheumatoid Arthritis | 0 | Feb 2023 | — | 2022-05-18 |
| Study of Remdesivir in Participants Below 18 Years Old With COVID-19NCT04431453results2023-12-22Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Remdesivir | COVID-19 | 59 | 2023-02-10actual | — | 2024-02-06 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug TherapyNCT04483687Proportion of Participants Who Achieve an Assessment of SpondyloArthritis international Society 40% Improvement (ASAS40) Response at Week 16Randomized · Double-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Development program terminated | Drug: Filgotinib, Placebo to Match Filgotinib | Ankylosing Spondylitis | 0 | Jan 2023 | — | 2021-01-11 |
| A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsNCT02510300observationalGrowth data as measured by body height | — | Terminatedsponsor's stated reason: The study stopped early because the study objectives were met. | Drug: Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) | Hepatitis C Virus Infection | 461 | 2023-01-06actual | — | 2023-01-27 |
| Study of Cilofexor in Adults With Primary Sclerosing CholangitisNCT03890120results2023-11-29Percentage of Participants With Progression of Liver Fibrosis at Blinded Phase Week 96Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis. | Drug: Cilofexor, Placebo | Primary Sclerosing Cholangitis | 419 | 2022-11-10actual | — | 2023-11-29 |
| Study to Assess the Effects of GS-3583 in Participants With Advanced Solid TumorsNCT04747470results2024-09-03Parts 1 and 2: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule, GS-3583. | Drug: GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel | Advanced Solid Tumors | 13 | 2022-11-07actual | — | 2024-09-03 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug TherapyNCT04483700Proportion of Participants Who Achieve an Assessment of SpondyloArthritis international Society 40% Improvement (ASAS40) Response at Week 16Randomized · Double-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Development program terminated | Drug: Filgotinib, Placebo to Match Filgotinib | Ankylosing Spondylitis | 0 | Oct 2022 | — | 2021-01-11 |
| Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)NCT04809623results2024-04-05Percentage of Participants Who Experienced Treatment-emergent Adverse EventsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: Edecesertib, Placebo, Standard of Care | Cutaneous Lupus Erythematosus | 3 | 2022-10-18actual | — | 2024-04-05 |
| Dose Optimization Study of Idelalisib in Follicular LymphomaNCT02536300results2023-08-14Overall Response Rate (ORR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Gilead has made the decision to close the study due to enrollment challenges | Drug: Idelalisib | Follicular Lymphoma | 96 | 2022-09-27actual | — | 2023-08-14 |
| Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersNCT03960645results2024-05-28Pharmacokinetic (PK) Parameter: AUCtau of Bictegravir (BIC)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: B/F/TAF | HIV-1-infection | 62 | 2022-07-21actual | — | 2024-06-14 |
| Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionNCT04811040results2025-01-27Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Week 26 Analysis ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 1 | Completed | Drug: Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab, Zinlirvimab | HIV-1 Infection | 32 | 2022-06-09actual | — | 2025-01-27 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaNCT04827589Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 8.Randomized · Double-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Development program terminated | Drug: Tirabrutinib, Placebo | Chronic Spontaneous Urticaria | 0 | Apr 2022 | — | 2021-07-28 |
| Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)NCT04745351results2023-05-12Percentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 29Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to study enrollment feasibility. This decision is not based on efficacy or safety concerns. | Drug: Remdesivir, RDV Placebo, Standard of Care | COVID-19 | 249 | 2022-04-20actual | — | 2023-05-12 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)NCT03852433results2024-07-29Percentage of Participants With Sustained Virological Response at Week 24 After the Scheduled End of Treatment (SVR24)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) | Chronic Hepatitis Delta | 175 | 2022-04-05actual | — | 2024-10-08 |
| Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaNCT04502706Percentage of Participants Experiencing Treatment-Emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision to discontinue development of this molecule | Drug: GS-0189, Rituximab | Non-hodgkin Lymphoma | 9 | 2022-03-31actual | — | 2023-06-05 |
| Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)NCT04009057observationalPercentage of Participants with HIV-1 RNA Suppression (HIV RNA < 50 copies/mL) at 12 Months after Initiating or Switching to B/F/TAF | — | Completed | Other: B/F/TAF | HIV-1-infection | 143 | 2022-03-21actual | — | 2022-05-03 |
| Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsNCT03547908results2023-03-15Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Statistical Analysis Plan - Interim Analysis ↗ · Statistical Analysis Plan: Statistical Analysis Plan - Final Analysis ↗ | Phase 3 | Completed | Drug: B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF | HIV-1/HBV Co-Infection | 244 | 2022-02-25actual | — | 2025-03-19 |
| Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ CancersNCT03912831results2023-12-26Phase 1A: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Development program terminated | Drug: KITE-439, Cyclophosphamide, Fludarabine, Interleukin-2 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | 8 | 2022-02-18actual | — | 2023-12-26 |
| A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C InfectionNCT02292706results2023-10-04observationalPercentage of Participants Maintaining Sustained Virologic Response (SVR) at Week 240Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: The study stopped early because the study objectives were met. | Drug: Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen · Other: Ineligible parent treatment | Hepatitis C Virus Infection | 1,609 | 2021-12-31actual | — | 2023-10-04 |
| Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in KoreaNCT02907996observationalPercentage of Participants Experiencing Any Adverse Events (AEs) Occurring During Administration of Sovaldi Regimens or Within 30 Days After Completion (or Discontinuation) of Sovaldi Treatment Regimens | — | Completed | Drug: Sofosbuvir | Hepatitis C Virus | 2,033 | 2021-12-09actual | — | 2021-12-27 |
| Safety Profile of Idelalisib in Patients With Refractory Follicular LymphomaNCT03568929observationalOverall Safety Profile of Idelalisib as Measured by the Incidence of Adverse Events (AE), Serious AEs, Special Situation Reports, Adverse Drug Reactions (ADR), and Serious ADRs | — | Completed | Drug: Idelalisib | Follicular Non-Hodgkin's Lymphoma Refractory | 257 | 2021-10-29actual | — | 2021-11-19 |
| Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594results2022-12-19Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot AlgorithmRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Week 28 Analysis ↗ · Statistical Analysis Plan: Week 54 Analysis ↗ · Statistical Analysis Plan: Week 80 Final Analysis ↗ | Phase 2 | Completed | Drug: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF | HIV-1-infection | 183 | 2021-10-05actual | — | 2024-10-02 |
| Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseNCT04026165results2022-12-21Treatment-specific Baseline Estimated Glomerular Filtration Rate Based on Creatinine (eGFRcr)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SEL, Placebo | Diabetic Kidney Disease | 384 | 2021-09-03actual | — | 2022-12-21 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisNCT04060147results2023-07-27Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The study enrollment was terminated early by the sponsor due to recruitment challenges. | Drug: Cilofexor | Primary Sclerosing Cholangitis, Compensated Cirrhosis | 11 | 2021-09-02actual | — | 2023-07-27 |
| Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in KoreaNCT02951364observationalIncidence of Adverse Events (AEs) and Special Situation Reports (SSRs) | — | Completed | Drug: LDV/SOF | Hepatitis C Virus | 1,081 | 2021-06-11actual | — | 2021-11-29 |
| Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406NCT04467684Pharmacokinetic ParametersRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: CB-0406 100 mg, CB-0406 200 mg, CB-0406 400 mg, CB-0406 800 mg, CB-0406 1,000 mg, Matched placebo | Healthy Volunteers | 90 | 2021-05-30actual | — | 2021-06-11 |
| Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient SettingNCT04501952results2021-11-16Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns. | Drug: RDV, Placebo to Match RDV | COVID-19 | 584 | 2021-05-06actual | — | 2021-11-16 |
| Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)NCT01906255observationalTreatment adherence, as measured by drug level, to the once-daily dosing regimen of FTC/TDF for PrEP | — | Completed | — | HIV | 10,577 | 2021-04-27actual | — | 2021-09-01 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid TumorsNCT04049617results2022-08-10Number of Participants Experiencing Dose Limiting Toxicities (DLTs) During the Dose Escalation PhaseNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Gilead decision to terminate | Drug: Evixapodlin | Advanced Solid Tumors | 18 | 2021-03-30actual | — | 2022-10-06 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated CirrhosisNCT04112303results2022-04-20Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 37 | 2021-03-26actual | — | 2022-04-20 |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsNCT03349346Incidence Rate of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the grounds that idelalisib is likely to be unsafe in paediatrics | Drug: Idelalisib, Rituximab, Ifosfamide, Carboplatin, Etoposide | Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma | 0 | Feb 2021 | — | 2018-12-11 |
| Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by InhalationNCT04539262results2022-03-03Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Remdesivir (RDV), Placebo | COVID-19 | 156 | 2021-02-26actual | — | 2022-03-03 |
| Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative ColitisNCT04130919results2022-08-24Percentage of Participants Who Achieved Clinical Remission Per Modified Mayo Clinic Score (MCS) at Week 10Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage | Drug: Tilpisertib, Placebo | Ulcerative Colitis | 19 | 2021-02-25actual | — | 2022-08-24 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's DiseaseNCT03077412results2022-04-08Percentage of Participants Who Achieved Combined Fistula Response at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Filgotinib, Placebo to match filgotinib | Fistulizing Crohn's Disease | 57 | 2021-01-20actual | — | 2022-04-08 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyNCT04115748results2022-05-16Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Development program terminated | Drug: Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab | Psoriatic Arthritis | 67 | 2021-01-19actual | — | 2022-05-16 |
| Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsNCT04608344results2022-01-19Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROSRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib | Rheumatoid Arthritis | 27 | 2021-01-13actual | — | 2022-06-14 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD TherapyNCT04115839results2022-03-18Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Development program terminated | Drug: Filgotinib, Placebo to match filgotinib | Psoriatic Arthritis | 106 | 2021-01-04actual | — | 2022-03-18 |
| Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell MalignanciesNCT02457559results2022-03-24Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Tirabrutinib | Relapsed/Refractory B-cell Malignancies | 29 | 2020-12-30actual | — | 2022-03-24 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisNCT03207815results2022-01-21Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Development program terminated | Drug: Filgotinib, Placebo to match filgotinib, Prednisone | Noninfectious Uveitis | 74 | 2020-12-29actual | — | 2022-01-21 |
| Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)NCT02781584results2022-02-02Percentage of Participants Who Experienced Treatment-Emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Cohort 1-9 SAP ↗ · Statistical Analysis Plan: Cohort 10-11 SAP ↗ · Statistical Analysis Plan: Cohort 12-13 SAP ↗ | Phase 2 | Completed | Drug: SEL, FIR, CILO, FENO, VAS | Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD) | 220 | 2020-12-17actual | — | 2022-03-16 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum ChemotherapyNCT03558139results2024-04-01Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Safety Run-in (Part 1)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Magrolimab, Avelumab | Ovarian Cancer | 34 | 2020-12-03actual | — | 2024-04-01 |
| Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)NCT03852719results2022-10-28Percentage of Participants With Combined Response at Week 48Randomized · Open-label · TreatmentStudy Protocol: Amendment 4 ↗ · Study Protocol: Amendment 6 ↗ · Statistical Analysis Plan: Week 48 Analysis ↗ · Statistical Analysis Plan: Week 96 Analysis ↗ · Statistical Analysis Plan: Week 144 Analysis ↗ · Statistical Analysis Plan: Week 192 Analysis ↗ · Statistical Analysis Plan: Statistical Analysis Plan: Week 240 Analysis ↗ | Phase 3 | Completed | Drug: Bulevirtide | Chronic Hepatitis Delta | 150 | 2020-11-26actual | — | 2025-08-22 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionNCT04211909results2021-10-27Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Study TreatmentNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL, SOF/VEL/VOX | Hepatitis C Virus Infection | 87 | 2020-11-12actual | — | 2021-10-27 |
| Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid TumorsNCT03954704results2023-11-21Phase 1a Part A: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs), Graded Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: The decision to discontinue the study was made based on the totality of the clinical, pharmacokinetic, and pharmacodynamic findings. No safety concerns were observed. | Drug: Dalutrafusp alfa, mFOLFOX6 Regimen, Dalutrafusp alfa | Advanced Solid Tumors | 22 | 2020-10-27actual | — | 2023-11-21 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)NCT03046056results2021-08-09Percentage of Participants Who Achieved Clinical Remission at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Filgotinib, Placebo to match filgotinib | Small Bowel Crohn's Disease | 78 | 2020-07-20actual | — | 2021-08-23 |
| Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)NCT03987074results2021-07-15Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Semaglutide, Firsocostat, Cilofexor | Nonalcoholic Steatohepatitis | 109 | 2020-07-13actual | — | 2021-07-15 |
| Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa BacteriaNCT03219164results2022-05-16Percentage of Participants With Pseudomonas Aeruginosa (PA)-Negative Cultures Through 28 Days Post-Treatment in the 14-Day Treatment Group vs 28-Day Treatment GroupRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic. | Drug: AZLI, Placebo | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis | 149 | 2020-05-27actual | — | 2022-06-14 |
| Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenNCT01854775results2021-05-24Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)Non-randomized · Open-label · TreatmentStudy Protocol: Protocol Amendment 6 ↗ · Study Protocol: Protocol Amendment 7 ↗ · Statistical Analysis Plan: Interim 4 Analysis ↗ · Statistical Analysis Plan: Interim 6 Analysis ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 2/3 | Completed | Drug: E/C/F/TAF, E/C/F/TAF (Low Dose) | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | 129 | 2020-05-11actual | — | 2026-01-09 |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care TreatmentNCT04292730results2021-01-26Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part A_f-redact ↗ · Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part B_f-redact ↗ | Phase 3 | Completed | Drug: Remdesivir, Standard of Care | COVID-19 | 1,113 | 2020-04-29actual | — | 2021-01-26 |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)NCT04292899results2020-12-31Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Part A ↗ · Statistical Analysis Plan: Part B ↗ | Phase 3 | Completed | Drug: Remdesivir, Standard of Care | COVID-19 | 4,891 | 2020-04-09actual | — | 2020-12-31 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisNCT02914522results2021-04-21Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Filgotinib, PTM filgotinib | Ulcerative Colitis | 1,351 | 2020-03-31actual | — | 2021-04-21 |
| Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)NCT02574455results2021-04-30Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) PopulationRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sacituzumab govitecan, Eribulin, Capecitabine, Gemcitabine, Vinorelbine | Breast Cancer | 529 | 2020-03-30actual | — | 2022-06-15 |
| ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)NCT03602560results2022-05-31Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: seladelpar 5-10 mg, seladelpar 10 mg, Placebo | Primary Biliary Cholangitis | 265 | 2020-02-16actual | — | 2022-08-02 |
| Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected ControllersNCT03060447results2021-04-21Percentage of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 1 | Completed | Drug: Vesatolimod, Placebo, ART | HIV-1 Infection | 25 | 2020-02-13actual | — | 2021-04-21 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal CancerNCT02953782results2021-03-01Percentage of Participants With Dose Limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Magrolimab, Cetuximab | Solid Tumor, Colorectal Cancer | 78 | 2020-02-10actual | — | 2021-03-01 |
| Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)NCT03434353results2022-04-04Percentage of Participants With ≥ 0.5 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Groups 1-3 and 5)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B. | Drug: Inarigivir Soproxil, TAF | Chronic Hepatitis B | 123 | 2020-01-20actual | — | 2022-04-04 |
| A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSCNCT04024813results2025-01-16Relative Change in Baseline Serum Alkaline Phosphatase (AP) at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522). | Drug: Seladelpar, Placebo to match Seladelpar | Primary Sclerosing Cholangitis | 1 | 2020-01-09actual | — | 2025-01-16 |
| Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on TreatmentNCT03615066results2021-01-06Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Selgantolimod, TAF | Chronic Hepatitis B | 67 | 2019-12-12actual | — | 2022-05-10 |
| Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant VirusNCT03472326results2021-01-05Part 1 Randomized Cohort: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 15Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: GS-9131 did not meet the targeted antiviral response | Drug: GS-9131, BIC, TAF, ARV regimen, DRV, RTV | HIV-1-infection | 21 | 2019-12-09actual | — | 2021-01-05 |
| Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) InfectionNCT03820258results2020-08-31Pharmacokinetic (PK) Parameter: AUCtau of SOF, GS-331007 (Metabolite of SOF), VEL, and VOXNon-randomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Terminatedsponsor's stated reason: SOF/VEL/VOX will not be evaluated in younger age groups. | Drug: SOF/VEL/VOX | Hepatitis C Virus Infection | 21 | 2019-12-04actual | — | 2020-10-23 |
| Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV InfectionNCT03022981results2020-10-08PK Lead-in Phase: AUCtau: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval of Velpatasvir (VEL)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF/VEL, SOF/VEL | Hepatitis C Virus Infection | 216 | 2019-11-19actual | — | 2020-10-08 |
| Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsNCT03739866results2020-12-09Part A and Part B: Maximum Reduction From Day 1 (Baseline) Through Day 10 in Plasma HIV-1 RNARandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Lenacapavir, Placebo, B/F/TAF, TAF | HIV-1 Infection | 53 | 2019-11-14actual | — | 2021-04-09 |
| Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenNCT02285114results2021-01-12Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Interim Analysis ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 2/3 | Completed | Drug: F/TAF, 3rd ARV agent, Boosted PIs | HIV-1 | 41 | 2019-11-04actual | — | 2025-06-27 |
| Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)NCT03449446results2020-12-03Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL | Nonalcoholic Steatohepatitis | 395 | 2019-10-30actual | — | 2020-12-03 |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction AdenocarcinomaNCT02862535results2020-12-24Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Study was terminated due to sponsor's decision to not pursue further development of andecaliximab in oncology | Drug: Andecaliximab, S-1, Cisplatin, Oxaliplatin, Nivolumab | Gastric Adenocarcinoma | 36 | 2019-10-25actual | — | 2020-12-24 |
| Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With IdelalisibNCT03701438observationalSeroconversion Rate: Proportion of Participants with Either a Pre-Vaccination Hemagglutination Inhibition (HI) Titer < 1:10 and a Post-Vaccination HI titer ≥ 1:40, or a Pre-Vaccination HI titer ≥ 1:10 and a ≥ 4-fold Increase in Post-Vaccination HI Titer | — | Terminatedsponsor's stated reason: The Swissmedic agency released Gilead from this post marketing requirement. | Biological: Influenza Vaccine | B-cell Malignancies | 2 | 2019-10-09actual | — | 2020-02-20 |
| Study of Ambrisentan in Participants With Pulmonary HypertensionNCT00777920results2020-09-30Percentage of Participants With Adverse Events (AEs) Associated With Long-Term Exposure to AmbrisentanOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Ambrisentan | Pulmonary Hypertension | 140 | 2019-09-11actual | — | 2020-09-30 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without CirrhosisNCT02943447results2020-01-13Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) in the Blinded Study PhaseRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC). | Drug: Cilofexor, Placebo to match cilofexor | Primary Biliary Cholangitis | 71 | 2019-09-04actual | — | 2020-09-22 |
| Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American ParticipantsNCT03631732results2020-08-27Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis SetRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Week 24 Analysis ↗ · Statistical Analysis Plan: Final Analysis ↗ · Statistical Analysis Plan: Week 48 Analysis ↗ | Phase 3 | Completed | Drug: B/F/TAF, NRTIs, Third Agent | HIV-1 Infection | 496 | 2019-08-12actual | — | 2021-09-05 |
| Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisNCT03053050results2020-06-29Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis According to the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network (CRN) Classification Without Worsening of NASH at Week 48Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol. | Drug: SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg | Nonalcoholic Steatohepatitis | 808 | 2019-06-19actual | — | 2020-06-29 |
| Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)NCT02968563results2020-07-01Rate of Complete Response/Complete Remission (CR), as Assessed by Investigator Using Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria at Week 25Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tirabrutinib, Idelalisib, Obinutuzumab | Chronic Lymphocytic Leukemia | 35 | 2019-06-17actual | — | 2022-01-21 |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )NCT01569295results2018-02-27Progression-Free Survival (PFS)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Idelalisib, Rituximab, Bendamustine, Placebo to match idelalisib | Chronic Lymphocytic Leukemia | 416 | 2019-06-10actual | — | 2020-03-10 |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNCT02545504results2020-04-28Overall Survival (OS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin | Gastric Adenocarcinoma | 432 | 2019-05-15actual | — | 2020-05-26 |
| A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT03551522results2022-07-05Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: unexpected histological findings | Drug: Seladelpar, Placebos | NASH - Nonalcoholic Steatohepatitis | 181 | 2019-05-08actual | — | 2022-09-15 |
| Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)NCT03053063results2020-05-07Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis According to the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network (CRN) Classification Without Worsening of NASHRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol. | Drug: SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg | Nonalcoholic Steatohepatitis | 883 | 2019-05-06actual | — | 2020-05-07 |
| Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic FunctionNCT02891408results2020-12-17Pharmacokinetic (PK) Parameter: AUClast of Firsocostat, GS-834773 (Primary Metabolite of Firsocostat), and Fenofibric Acid (Primary Metabolite of Fenofibrate)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Firsocostat, Fenofibrate | Nonalcoholic Steatohepatitis (NASH) | 74 | 2019-05-05actual | — | 2020-12-17 |
| Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)NCT03285711results2020-05-18Percent Change in Urine Protein From Baseline (Day 1) to Week 16Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo | Lupus Membranous Nephropathy | 9 | 2019-05-03actual | — | 2020-05-18 |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsNCT01803282results2020-05-04Percentage of Participants Experiencing Treatment-Emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Andecaliximab, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed, Leucovorin, Oxaliplatin, 5-FU, Bevacizumab, Irinotecan, Paclitaxel | Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer | 236 | 2019-04-23actual | — | 2020-06-02 |
| Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)NCT03180619results2020-04-09Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: TAF | Chronic Hepatitis B | 124 | 2019-03-27actual | — | 2021-09-27 |
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandNCT03582098observationalOverall Response Rate | — | Completed | Drug: Idelalisib, Rituximab | Chronic Lymphocytic Leukaemia | 112 | 2019-03-26actual | — | 2019-04-12 |
| Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis BNCT03491553results2020-04-01Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Week 24 Analysis and Final Analysis ↗ · Statistical Analysis Plan: TFFU (Treatment-Free Follow-Up) Analysis ↗ | Phase 2 | Completed | Drug: Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy | Chronic Hepatitis B | 48 | 2019-03-22actual | — | 2021-08-19 |
| Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)NCT03134222results2020-04-08Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lanraplenib, Filgotinib, Lanraplenib placebo, Filgotinib placebo | Cutaneous Lupus Erythematosus | 47 | 2019-03-13actual | — | 2020-06-09 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2019-03-01actual | — | 2021-08-12 |
| Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsNCT03135028results2020-03-06Percentage of Participants With Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: No signal of efficacy with Entospletinib | Drug: Entospletinib, Daunorubicin, Cytarabine | Hematologic Malignancy, Acute Myeloid Leukemia | 9 | 2019-02-26actual | — | 2020-03-06 |
| Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)NCT02983617results2020-02-28Rate of Complete Remission/Complete Remission With Incomplete Recovery of the Bone Marrow (CR/CRi), as Assessed by Investigator Using Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Criteria at Week 25Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tirabrutinib, Entospletinib, Obinutuzumab | Chronic Lymphocytic Leukemia | 36 | 2019-02-20actual | — | 2021-12-21 |
| Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed AdultsNCT02858401results2020-02-21Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and Any Treatment-Emergent Adverse Events (AEs).Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vesatolimod, Placebo, ARV regimen | HIV-1 Infection | 48 | 2019-02-14actual | — | 2020-02-21 |
| Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeNCT03100942results2020-01-22Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to BaselineRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo | Sjogren's Syndrome | 152 | 2019-01-10actual | — | 2020-10-23 |
| Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380results2019-11-20Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo | HIV-1-infection | 567 | 2018-12-04actual | — | 2022-01-11 |
| CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesNCT02678338Maximum tolerated dose (MTD) of Hu5F9-G4, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Part A)Open-label · Treatment | Phase 1 | Completed | Drug: Hu5F9-G4 | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 20 | Nov 2018actual | — | 2019-02-21 |
| Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal DiseaseNCT03036839results2019-12-09Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C Virus Infection | 95 | 2018-11-22actual | — | 2020-03-02 |
| Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 YearsNCT03405935results2019-12-05Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot AlgorithmOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: B/F/TAF | HIV-1 Infection | 86 | 2018-11-20actual | — | 2020-12-01 |
| Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)NCT02404220results2019-12-02Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol: Amendment 5 ↗ | Phase 1/2 | Terminated | Drug: Entospletinib, Vincristine, Dexamethasone, CNS Prophylaxis | Acute Lymphoblastic Leukemia | 30 | 2018-11-16actual | — | 2020-01-02 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer ChemotherapyNCT02868242results2019-08-20Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C Virus Infection | 19 | 2018-11-12actual | — | 2020-03-02 |
| Phase 1 Trial of Hu5F9-G4, a CD47-targeting AntibodyNCT02216409Safety and Tolerability of Hu5F9-G4Open-label · Treatment | Phase 1 | Completed | Drug: Hu5F9-G4 | Solid Tumor | 88 | Oct 2018actual | — | 2019-02-05 |
| Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic FunctionNCT02808312results2020-09-30Pharmacokinetic (PK) Parameter: AUClast of CilofexorNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Cilofexor | Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | 57 | 2018-10-16actual | — | 2021-01-07 |
| Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184INCT02616029results2019-11-04Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E/C/F/TAF | HIV-1 Infection | 66 | 2018-10-11actual | — | 2020-07-23 |
| Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyNCT02886728results2021-01-15Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX | Rheumatoid Arthritis | 1,252 | 2018-10-05actual | — | 2021-06-01 |
| Pharmacokinetics of Lanraplenib in Adults With Impaired Renal FunctionNCT02959138results2019-10-25Pharmacokinetic (PK) Parameter: AUClast of Lanraplenib Presented Based on Range of CLcrNon-randomized · Open-label · TreatmentStudy Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Lanraplenib. | Inflammatory Disease | 36 | 2018-10-05actual | — | 2019-10-25 |
| Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C CirrhosisNCT02994056results2019-10-08Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF/VEL, RBV | Hepatitis C Virus Infection | 32 | 2018-09-25actual | — | 2020-03-02 |
| Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically SuppressedNCT02979613results2019-09-25Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US FDA)-Defined Snapshot AlgorithmRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: TAF, TDF, TAF Placebo, TDF Placebo | Chronic Hepatitis B | 490 | 2018-09-10actual | — | 2020-09-14 |
| Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)NCT02955602results2022-07-14Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule | Primary Biliary Cirrhosis | 119 | 2018-09-07actual | — | 2022-07-14 |
| Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)NCT02343939results2019-11-15Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine | Acute Myeloid Leukemia | 148 | 2018-09-04actual | — | 2019-11-15 |
| Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaNCT01659021results2017-03-31Progression-Free SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminated | Drug: Idelalisib, Ofatumumab | Chronic Lymphocytic Leukemia | 261 | 2018-08-15actual | — | 2019-08-14 |
| Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal DiseaseNCT03036852results2019-11-12Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF/VEL | Chronic Hepatitis C | 59 | 2018-08-13actual | — | 2020-03-06 |
| Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionNCT03417778results2021-01-15Pharmacokinetic (PK) Parameter: AUClast of FilgotinibNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Filgotinib | Rheumatoid Arthritis | 20 | 2018-08-09actual | — | 2021-01-15 |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerNCT02983604results2019-08-07Phase 1b Dose Escalation: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) Through Day 28 at Each Dose Level of GS-5829Non-randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: GS-5829, Exemestane, Fulvestrant | Advanced Estrogen Receptor Positive HER2- Breast Cancer | 14 | 2018-07-19actual | — | 2019-08-07 |
| Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateNCT02889796results2021-01-19Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX | Rheumatoid Arthritis | 1,759 | 2018-07-04actual | — | 2021-06-09 |
| Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV InfectionNCT02175758results2019-04-30For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)Non-randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Study Protocol: Amendment 5 ↗ · Study Protocol: Amendment 6 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF, RBV | Hepatitis C Virus Infection | 106 | 2018-06-21actual | — | 2019-04-30 |
| Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical PracticeNCT02783976observationalProportion of participants experiencing adverse drug reactions (ADRs), serious adverse events (SAEs), and adverse events (AEs) during the treatment period and posttreatment follow-up period | — | Completed | Drug: Sovaldi | HCV Infection | 25 | 2018-06-20actual | — | 2018-10-02 |
| An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib StudyNCT01090414results2019-08-28Overall Response RateOpen-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Study Protocol: Amendment 5 ↗ · Study Protocol: Amendment 6 ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: Idelalisib | Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin | 202 | 2018-06-18actual | — | 2019-08-28 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-InfectionNCT02249182results2019-04-24For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOFNon-randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Study Protocol: Amendment 5 ↗ · Study Protocol: Amendment 6 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LDV/SOF, RBV | Hepatitis C Virus Infection | 226 | 2018-06-15actual | — | 2020-03-02 |
| Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)NCT01539291results2019-08-20Progression-Free Survival (PFS)Randomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Study Protocol: Amendment 5 ↗ · Study Protocol: Amendment 6 ↗ · Study Protocol: Amendment 7 ↗ · Statistical Analysis Plan: Blinded ↗ · Statistical Analysis Plan: Open Label ↗ · Study Protocol: Amendment 8 ↗ · Study Protocol: Amendment 9 ↗ | Phase 3 | Terminated | Drug: Idelalisib | Chronic Lymphocytic Leukemia | 161 | 2018-05-21actual | — | 2019-08-20 |
| Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsNCT03369002Maximum plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: seladelpar | Hepatic Impairment | 32 | 2018-05-15actual | — | 2018-05-18 |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasNCT01282424results2014-09-04Overall Response RateOpen-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol: Amendment 10 (Version 9.0) ↗ | Phase 2 | Completed | Drug: Idelalisib | Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma | 125 | 2018-05-02actual | — | 2019-07-11 |
| A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseNCT01457768observationalProportion of participants with at least one drug resistant mutation (DRM) loss from enrollment to end of study by treatment regimen | — | Completed | — | Hepatitis C, Chronic | 570 | 2018-04-09actual | — | 2018-05-04 |
| Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentNCT02873936results2021-01-15Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12Randomized · Double-masked · TreatmentStudy Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Filgotinib, Placebo to match filgotinib, csDMARDs | Rheumatoid Arthritis | 449 | 2018-03-20actual | — | 2021-05-13 |
| Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment StudyNCT03118843results2019-04-03Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL/VOX | Hepatitis C Virus Infection | 31 | 2018-03-19actual | — | 2019-04-03 |
| A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP IndicationNCT01865786observationalPresence or absence of congenital malformations among infants born to HIV-1 uninfected women on FTC/TDF for PrEP | — | Completed | — | HIV Infection | 99 | 2018-03-13actual | — | 2018-03-30 |
| Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus InfectionNCT02479880results2019-05-20Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96Randomized · Open-label · OtherStudy Protocol: Original ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminated | Drug: Tenofovir DF · Radiation: DEXA Scan | Hepatitis B | 30 | 2018-02-28actual | — | 2019-05-20 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without CirrhosisNCT02943460results2019-03-12Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded PhaseRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Cilofexor, Placebo to match cilofexor | Primary Sclerosing Cholangitis | 52 | 2018-02-28actual | — | 2021-06-07 |
| Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsNCT02616783results2019-02-19Percent Change From Baseline to Week 48 in Spine BMDRandomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E/C/F/TAF, TDF, FTC, FTC/TDF, 3TC, Third agent | HIV-1 Infection | 167 | 2018-02-21actual | — | 2020-03-04 |
| Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)NCT02854631results2019-02-06Percentage of Participants With Treatment-Emergent (TE) Adverse Events (AE), Serious AEs (SAE), AEs Leading to Premature Study Drug Discontinuation, and Grade 3 or 4 Laboratory AbnormalitiesRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Selonsertib, Prednisolone, Placebo | Alcoholic Hepatitis (AH) | 104 | 2018-02-16actual | — | 2019-02-06 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisNCT02996682results2019-02-26Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL, RBV | Hepatitis C Virus Infection | 102 | 2018-02-13actual | — | 2019-02-26 |
| Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver TransplantNCT02862548results2019-02-26Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine EquationRandomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan: Week 24 Analysis ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 2 | Completed | Drug: TAF, TDF, Other approved antivirals | Chronic Hepatitis B | 51 | 2018-02-08actual | — | 2022-06-08 |
| Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionNCT03074331results2019-03-19Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 130 | 2018-02-07actual | — | 2019-03-19 |
| A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USANCT01865799observationalDrug utilization of uninfected individuals who are prescribed FTC/TDF for a PrEP indication, including gaps in therapy | — | Completed | — | Pre-exposure Prophylaxis for Prevention of HIV Infection | 64,186 | 2018-01-22actual | — | 2018-03-27 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver TransplantationNCT02728206results2019-02-06Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 9 | 2018-01-16actual | — | 2019-02-06 |
| Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)NCT02854605results2019-01-29Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Randomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GS-9674, Placebo to match GS-9674 | Nonalcoholic Steatohepatitis (NASH) | 140 | 2018-01-09actual | — | 2019-01-29 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCVNCT02671500results2019-01-08Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 375 | 2018-01-05actual | — | 2019-01-08 |
| Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820NCT02739360results2019-01-16Number of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and DeathsOpen-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminated | Drug: Idelalisib | Lymphoid Malignancies | 3 | 2017-12-28actual | — | 2020-03-04 |
| Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)NCT02701634results2018-12-26Best Overall Response RateRandomized · Double-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ | Phase 2 | Terminated | Drug: ENTO, Placebo | Chronic Graft Versus Host Disease | 66 | 2017-12-19actual | — | 2018-12-26 |
| Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TCNCT02469246results2018-06-11Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot AlgorithmRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Week 48 ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 3 | Completed | Drug: F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent | HIV-1 Infection | 567 | 2017-12-11actual | — | 2019-10-25 |
| Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in IndiaNCT02592057observationalIncidence of adverse drug reactions (ADRs) during treatment and up to 4 weeks after discontinuation of a SOF-based regimen | — | Completed | Drug: SOF | Hepatitis C Virus | 532 | 2017-11-30actual | — | 2018-05-15 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed DiseaseNCT02436135results2020-08-14Percentage of Participants Experiencing Any Treatment Emergent Adverse Events Within 28 Days of Idelalisib ExposureNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminated | Drug: Idelalisib, Ruxolitinib | Myelofibrosis | 10 | 2017-11-20actual | — | 2020-09-16 |
| Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaNCT02864381results2020-09-18Objective Response Rate (ORR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Final ↗ · Statistical Analysis Plan: Follow-up Analysis ↗ | Phase 2 | Completed | Drug: Andecaliximab, Nivolumab | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 144 | 2017-11-08actual | — | 2020-09-18 |
| Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric ParticipantsNCT01923311results2018-07-11Pharmacokinetic (PK) Parameter: AUCtau of EVGNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminated | Drug: EVG, Background regimen | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | 31 | 2017-11-03actual | — | 2018-08-09 |
| Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus InfectionNCT02591277observationalIncidence of adverse drug reaction (ADR) under real world settings | — | Completed | Drug: Harvoni | Hepatitis C | 3,294 | 2017-11-01actual | — | 2019-02-06 |
| A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)NCT01902472observationalSeroconversion rate among all subjects exposed to emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) (Truvada®) for a PrEP indication | — | Completed | — | HIV | 172 | 2017-10-30actual | — | 2020-07-14 |
| Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver FunctionNCT02521376results2019-07-26Pharmacokinetic (PK) Parameter: AUCtau of ENTONon-randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Entospletinib | Oncology | 56 | 2017-10-25actual | — | 2019-07-26 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate CancerNCT02607228results2020-12-08Phase 1b Dose Escalation: Number of Participants Experienced Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: Alobresib, Enzalutamide | Metastatic Castrate-Resistant Prostate Cancer | 31 | 2017-10-25actual | — | 2020-12-08 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerNCT02392611results2020-12-29Number of Participants Experiencing Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Alobresib, Exemestane, Fulvestrant | Solid Tumors and Lymphomas | 33 | 2017-10-11actual | — | 2020-12-29 |
| Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenNCT02652624results2018-11-02Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot AlgorithmRandomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan: Week 48 Statistical Analysis Plan ↗ · Statistical Analysis Plan: Final Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF | HIV-1 Infection | 472 | 2017-10-09actual | — | 2020-03-04 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and CirrhosisNCT02781558results2018-10-30Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)Randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Protocol Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF/VEL, RBV | Hepatitis C Virus Infection | 204 | 2017-10-06actual | — | 2018-11-27 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisNCT02600819results2018-10-16GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48Non-randomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 2.1 ↗ | Phase 3 | Completed | Drug: E/C/F/TAF, B/F/TAF | HIV-1 Infection | 55 | 2017-09-29actual | — | 2020-11-05 |
| Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic MalignanciesNCT01799889results2020-09-23Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor's decision to discontinue development of entospletinib. | Drug: Entospletinib MM, Entospletinib SDD | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | 326 | 2017-09-14actual | — | 2020-11-19 |
| Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentNCT02707601results2018-10-09Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)Randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E/C/F/TAF, F/R/TAF, LDV/SOF | HIV-1 Infection, HCV Infection | 150 | 2017-09-14actual | — | 2018-11-14 |
| Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateNCT02885181results2018-09-19Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28 (CRP)) at Week 12Randomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate | Rheumatoid Arthritis | 83 | 2017-08-22actual | — | 2018-09-19 |
| Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B InfectionNCT02258581observationalProportion of participants with serum hepatitis B surface antigen (HBsAg) decline ≥ 0.5 log10 IU/ml from baseline at Week 48 | — | Terminated | Drug: GS-4774, GS-9620, Tenofovir disoproxil fumarate (TDF) | Chronic Hepatitis B | 241 | 2017-08-14actual | — | 2017-10-03 |
| Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver TransplantNCT02781571results2018-08-21Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 79 | 2017-07-28actual | — | 2018-11-14 |
| Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal InsufficiencyNCT01958281results2018-08-08Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Statistical Analysis Plan: Statistical Analysis Plan for Cohorts 1 and 2 ↗ · Statistical Analysis Plan: Statistical Analysis Plan for Cohort 3 ↗ | Phase 2 | Completed | Drug: SOF, RBV, LDV/SOF | HCV Infection | 38 | 2017-07-18actual | — | 2018-08-08 |
| Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic SteatohepatitisNCT02856555results2020-07-24Percentage of Participants Experiencing Treatment-Emergent Adverse EventsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Firsocostat, Placebo | Nonalcoholic Steatohepatitis (NASH) | 127 | 2017-07-18actual | — | 2020-07-24 |
| Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory TractNCT02254408results2018-08-06Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9Randomized · Quadruple-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 5 ↗ · Study Protocol: Amendment 6 ↗ · Study Protocol: Amendment 7 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Presatovir, Placebo | Respiratory Syncytial Virus | 189 | 2017-07-14actual | — | 2018-08-06 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV InfectionNCT02021656results2018-12-28Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LDV/SOF | Chronic HCV Infection | 384 | 2017-07-08actual | — | 2020-03-05 |
| Effect of Andecaliximab on FEV1 in Adults With Cystic FibrosisNCT02759562results2018-07-05Absolute Change in Pre-bronchodilator FEV1 Percent Predicted From Baseline to Week 8Randomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Discontinuation of development for this indication | Drug: Andecaliximab, Placebo | Cystic Fibrosis | 6 | 2017-07-06actual | — | 2018-08-17 |
| Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic LeukemiaNCT02538614results2020-11-25Phase 1b: Percentage of Participants Experienced Dose Limiting Toxicities (DLTs) During the First 7 Weeks of Study TherapyNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminated | Drug: Idelalisib, BI 836826 | Chronic Lymphocytic Leukemia (CLL) | 2 | 2017-07-05actual | — | 2020-11-25 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus InfectionNCT02722837results2018-07-17Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 119 | 2017-06-26actual | — | 2018-11-16 |
| Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisNCT02862574results2018-06-27Change From Baseline in DAS28(CRP) at Week 12Randomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated by sponsor and decision was not due to any safety signals. | Drug: Andecaliximab, Placebo, Methotrexate, TNF Inhibitor | Rheumatoid Arthritis | 15 | 2017-06-26actual | — | 2018-06-27 |
| Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsNCT02605954results2018-07-13Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24Randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent | HIV-1 Infection | 275 | 2017-06-14actual | — | 2018-11-14 |
| Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionNCT02562742observationalIncidence of adverse drug reaction (ADR) under real world settings | — | Completed | Drug: SOF, REB | Hepatitis C | 554 | 2017-06-12actual | — | 2017-08-01 |
| Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionNCT02537379observationalIncidence of adverse drug reaction (ADR) under real world settings | — | Completed | Drug: SOF, COPE | Hepatitis C Virus Infection | 552 | 2017-06-05actual | — | 2017-06-27 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing RegimenNCT02822794results2018-07-03Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: SOF/VEL, RBV | Hepatitis C Virus Infection | 117 | 2017-06-02actual | — | 2018-11-14 |
| Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsNCT02603107results2018-06-06Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot AlgorithmRandomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan: Week 48 ↗ · Statistical Analysis Plan: Final ↗ | Phase 3 | Completed | Drug: RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF | HIV-1 Infection | 578 | 2017-05-15actual | — | 2020-12-29 |
| Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607956results2018-06-06Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan: Original ↗ · Statistical Analysis Plan: Amendment 1 ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 3 | Completed | Drug: DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo | HIV-1 Infection | 657 | 2017-05-12actual | — | 2022-03-07 |
| Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedNCT02603120results2018-07-23Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot AlgorithmRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo | HIV-1 Infection | 567 | 2017-05-09actual | — | 2020-11-12 |
| Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607930results2018-07-23Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan: Original ↗ · Statistical Analysis Plan: Amendment 1 ↗ · Statistical Analysis Plan: Final Analysis ↗ | Phase 3 | Completed | Drug: ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo | HIV-1 Infection | 631 | 2017-05-09actual | — | 2022-03-02 |
| Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory TractNCT02254421results2018-05-11Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9Randomized · Quadruple-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 5 (Amendment 4 not implemented) ↗ · Study Protocol: Amendment 6 ↗ · Study Protocol: Amendment 7 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Presatovir, Placebo | Respiratory Syncytial Virus Infection | 60 | 2017-04-17actual | — | 2018-09-24 |
| Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)NCT02836236results2018-04-18Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48Randomized · Double-masked · TreatmentStudy Protocol: Amendment 2.1 ↗ · Study Protocol: Amendment 3.1 ↗ · Study Protocol: Amendment 3.4 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Week 48 ↗ · Statistical Analysis Plan: Statistical Analysis Plan Final ↗ | Phase 3 | Completed | Drug: TAF, TDF, TAF Placebo, TDF Placebo | HBV, Chronic HBV Infection | 155 | 2017-04-05actual | — | 2024-10-02 |
| Registry Study for Patients With Chronic HBV Receiving Nucleotide TherapyNCT01590615observationalProportion of participants with a confirmed increase in serum creatinine from baseline of at least one grade | — | Completed | Drug: Anti-HBV nucleoside/nucleotide therapy | Hepatitis B | 54 | 2017-04-04actual | — | 2017-04-24 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLNCT01728207Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study was stopped due to insufficient efficacy and very slow accrual | Drug: IMMU-114 | Non-hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 30 | Mar 2017actual | — | 2021-08-19 |
| Gilead Sustained Virologic Response (SVR) RegistryNCT01457755observationalProportion of participants maintaining SVR at Week 144 by treatment regimen | — | Completed | — | Hepatitis C, Chronic | 6,625 | 2017-03-28actual | — | 2018-08-31 |
| Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) InfectionNCT02135614results2018-05-11Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5Randomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Study Protocol: Amendment 4 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Presatovir, Presatovir placebo | Respiratory Syncytial Virus Infection | 189 | 2017-03-27actual | — | 2018-09-24 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based TherapiesNCT02600351results2018-04-11Percentage of Participants With Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)Randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Due to lack of feasibility of enrolling participants, the study was terminated early. | Drug: LDV/SOF, RBV | Hepatitis C Virus Infection | 87 | 2017-03-21actual | — | 2018-11-16 |
| Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)NCT02836249results2018-04-17Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: TAF, TDF, TAF Placebo, TDF Placebo | HBV, Chronic HBV Infection | 181 | 2017-03-21actual | — | 2024-10-15 |
| Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) InfectionNCT02534350results2018-11-28Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis SetRandomized · Double-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Statistical Analysis Plan ↗ · Study Protocol: Amendment 2 ↗ | Phase 2 | Completed | Drug: Presatovir, Placebo | Respiratory Syncytial Virus (RSV) | 61 | 2017-02-20actual | — | 2018-11-28 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV InfectionNCT02738333results2018-03-14Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LDV/SOF, SOF, RBV | Hepatitis C Virus Infection | 239 | 2017-02-14actual | — | 2018-11-16 |
| Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to EmtricitabineNCT00743340results2018-04-26Number of Participants Who Had Access to, and Received the InterventionOpen-label · OtherStatistical Analysis Plan ↗ · Study Protocol: Amendment ↗ · Study Protocol: Original ↗ | Phase 2 | Completed | Drug: Emtricitabine | HIV-1 Infection | 50 | 2017-02-13actual | — | 2018-04-26 |
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic CardiomyopathyNCT02291237results2018-03-22Change in Peak Oxygen Uptake (VO2) Achieved During Cardiopulmonary Exercise Testing (CPET) From Baseline to Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol: Original ↗ · Study Protocol: Amendment 1 ↗ · Study Protocol: Amendment 2 ↗ · Study Protocol: Amendment 3 ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminated | Drug: Eleclazine, Placebo | Hypertrophic Cardiomyopathy | 172 | 2017-01-20actual | — | 2018-09-24 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being TreatedNCT02579382results2020-05-18Mean Change (Measured in log10 IU/mL) in Hepatitis B Surface Antigen (HBsAg) From Baseline at Week 24Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TDF, Vesatolimod, Placebo | Chronic Hepatitis B | 192 | 2017-01-16actual | — | 2020-05-18 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV CoinfectionNCT02613871results2018-02-13Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF | Hepatitis C Virus Infection | 111 | 2017-01-04actual | — | 2020-03-06 |
| Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal CancerNCT01605318Percentage of Participants With Adverse Events and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminated | Drug: Labetuzumab Govitecan (LG) | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | 92 | 2017-01-03actual | — | 2024-01-24 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLNCT01101581Safety/dose limiting toxicityRandomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: No subjects enrolled | Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab | Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma | 0 | Dec 2016actual | — | 2021-08-18 |
| Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis PatientsNCT01375036observationalProportion of participants whose least susceptible Pseudomonas aeruginosa (PA) isolate has a ≥ 4-fold increase in aztreonam minimum inhibitory concentration over 1 year and is above the parenteral breakpoint (> 8 μg/mL) | — | Completed | — | Cystic Fibrosis | 510 | Dec 2016actual | — | 2017-01-11 |
| Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3NCT02300558results2018-01-12Change From Baseline in Mean Daytime QT Interval in Lead V5 Corrected for Heart Rate Using the Fridericia Formula (QTcF) Interval to Week 24 (Based on Standard 12-lead ECG Data)Non-randomized · Single-masked · Treatment | Phase 3 | Terminated | Drug: Eleclazine, Eleclazine placebo | Long QT Syndrome Type 3 | 41 | 2016-12-12actual | — | 2018-01-12 |
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLNCT01585688Evaluate the safety and tolerability of hLL1-DOXOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued | Drug: hLL1-DOX (IMMU-115) | Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | 13 | Nov 2016actual | — | 2021-10-08 |
| Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic CancerNCT01956812overall survivalRandomized · Triple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo. | Drug: IMMU-107, placebo, Gemcitabine | Metastatic Pancreatic Cancer, Pancreatic Cancer | 334 | Nov 2016actual | — | 2021-08-16 |
| Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's DiseaseNCT02405442results2019-03-28Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind PhaseRandomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: Andecaliximab, Placebo | Crohn's Disease | 187 | 2016-11-30actual | — | 2019-04-23 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV InfectionNCT02487030results2017-12-14Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Hepatitis C Virus Infection | 255 | 2016-11-11actual | — | 2018-11-16 |
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsNCT02276612results2018-02-22Incidence of Treatment-Emergent Serious Adverse EventsOpen-label · Treatment | Phase 2/3 | Completed | Drug: E/C/F/TAF | HIV | 60 | 2016-11-10actual | — | 2018-11-19 |
| Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and CirrhosisNCT02639338results2017-11-14Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL/VOX, SOF/VEL | Hepatitis C Virus Infection | 220 | 2016-10-12actual | — | 2019-03-05 |
| Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3NCT02466516results2019-06-26Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory AbnormalityRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: SEL · Biological: SIM | Non-Alcoholic Steatohepatitis (NASH) | 72 | 2016-10-11actual | — | 2019-06-26 |
| Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral TherapyNCT02607735results2017-12-13Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) (Primary Study)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: SOF/VEL/VOX, Placebo | Hepatitis C | 416 | 2016-10-10actual | — | 2019-03-05 |
| Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral TherapyNCT02607800results2017-11-08Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL/VOX, SOF/VEL | Hepatitis C | 943 | 2016-10-10actual | — | 2019-03-05 |
| Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A InhibitorNCT02639247results2017-11-06Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL/VOX, SOF/VEL | Hepatitis C Virus Infection | 333 | 2016-10-05actual | — | 2019-03-05 |
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)NCT02568683results2019-04-17Number of Participants With Adverse Events (AEs) and Laboratory (Lab) Abnormalities Defined as Dose Limiting Toxicities (DLTs) in Participants With Relapsed or Refractory B-cell NHL: Dose Escalation StageNon-randomized · Open-label · Treatment | Phase 1/2 | Terminated | Drug: Entospletinib, Vincristine | Non-Hodgkin Lymphoma | 10 | 2016-10-03actual | — | 2019-04-17 |
| Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-DefibrillatorNCT02104583results2019-04-09Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Eleclazine, Placebo to match eleclazine | Ventricular Arrhythmia | 313 | Sep 2016actual | — | 2019-04-09 |
| Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative ColitisNCT02520284results2019-04-10For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8Randomized · Double-masked · Treatment | Phase 2/3 | Terminated | Biological: Andecaliximab, Placebo | Ulcerative Colitis | 165 | Sep 2016actual | — | 2019-04-10 |
| Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASHNCT01672879results2019-03-27Change From Baseline in Hepatic Venous Pressure Gradient (HVPG)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminated | Biological: Placebo, SIM | Liver Fibrosis Due to NASH | 259 | 2016-09-26actual | — | 2019-03-27 |
| Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)NCT02626026results2020-09-09Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Tirabrutinib, Placebo | Rheumatoid Arthritis | 42 | 2016-09-01actual | — | 2020-09-09 |
| Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerNCT02161679Progression Free SurvivalRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated | Drug: IMMU-132 infusion is administered to participants in one arm for the study, IMMU-132 plus Carboplatin infusion | Triple-negative Breast Cancer | 0 | Aug 2016actual | — | 2021-08-19 |
| GS-6615 in Adults With Chronic Stable Angina and Coronary Artery DiseaseNCT02377336Change from baseline in time to 1 mm ST-segment depressionRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Anticipated recruitment challenges | Drug: GS-6615, Placebo | Ischemic Heart Disease | 0 | Aug 2016 | — | 2015-06-08 |
| Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV InfectionNCT02021643results2018-02-20Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Sofosbuvir, RBV, PEG | Chronic HCV Infection | 687 | 2016-08-12actual | — | 2018-02-20 |
| Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)NCT01672853results2019-10-22Change From Baseline in MQC on Liver Biopsy at Week 96Randomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: Simtuzumab, Placebo | Primary Sclerosing Cholangitis (PSC) | 235 | 2016-08-08actual | — | 2019-10-22 |
| Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)NCT01672866results2019-03-27Change From Baseline in MQC on Liver BiopsyRandomized · Triple-masked · Treatment | Phase 2 | Terminated | Biological: Placebo, SIM | Liver Fibrosis Due to NASH | 222 | 2016-08-02actual | — | 2019-03-27 |
| Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney DiseaseNCT02177786results2019-06-11Change in eGFR From Baseline at Week 48Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Selonsertib, Placebo to match selonsertib | Diabetic Kidney Disease | 334 | Jul 2016actual | — | 2019-11-05 |
| Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHBNCT01320943results2017-08-29Proportion of Participants With HBsAg Loss at Week 144 in Both Study ArmsRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: TDF · Other: Stop TDF | Chronic Hepatitis B | 43 | 2016-07-28actual | — | 2017-08-29 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and PharmacodynamicsNCT02654002results2020-10-12Single-Dose Pharmacokinetic (PK) Parameter: AUClast of CilofexorRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Cilofexor, Placebo | Nonalcoholic Steatohepatitis (NASH) | 120 | 2016-07-14actual | — | 2020-10-12 |
| Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment StudyNCT02300103results2017-07-28Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: SOF/VEL, RBV | Hepatitis C Virus Infection | 69 | 2016-07-02actual | — | 2018-11-16 |
| Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)NCT02609048results2025-02-25Baseline Alkaline Phosphatase (AP) LevelsRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction. | Drug: Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg | Primary Biliary Cirrhosis (PBC) | 41 | 2016-07-01actual | — | 2025-02-25 |
| Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected AdultsNCT02345226results2017-10-19Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-defined Snapshot AlgorithmRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo | HIV-1 Infection | 881 | 2016-06-29actual | — | 2020-01-02 |
| Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)NCT02345252results2017-12-08Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo | HIV-1 Infection | 632 | 2016-06-22actual | — | 2020-01-02 |
| A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid MalignanciesNCT01705847Maximum tolerated dose (MTD)Open-label · Treatment | Phase 1 | Completed | Drug: GS-9820 | Lymphoid Malignancies | 39 | May 2016actual | — | 2016-05-17 |
| Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaNCT01980888results2017-10-11Progression-Free SurvivalRandomized · Double-masked · Treatment | Phase 3 | Terminated | Drug: Idelalisib, Bendamustine, Rituximab, Placebo | Chronic Lymphocytic Leukemia | 311 | 2016-05-30actual | — | 2018-11-19 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasNCT01732913results2017-05-11Progression Free SurvivalRandomized · Triple-masked · Treatment | Phase 3 | Terminated | Drug: Placebo, Rituximab, Idelalisib | Indolent Non-Hodgkin's Lymphomas | 295 | 2016-05-18actual | — | 2018-11-16 |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasNCT01732926results2017-05-11Progression-free Survival (PFS)Randomized · Triple-masked · Treatment | Phase 3 | Terminated | Drug: Idelalisib, Rituximab, Bendamustine, Placebo | Indolent Non-Hodgkin's Lymphomas | 475 | 2016-05-17actual | — | 2018-11-16 |
| Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic LeukemiaNCT01980875results2017-06-28Progression-Free SurvivalRandomized · Open-label · Treatment | Phase 3 | Terminated | Drug: Idelalisib, Chlorambucil, Obinutuzumab | Chronic Lymphocytic Leukemia | 57 | 2016-05-13actual | — | 2018-11-19 |
| Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 SyndromeNCT02365506results2020-12-30Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3: Lead V5Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Eleclazine, Placebo | LQT2 Syndrome | 13 | 2016-05-13actual | — | 2020-12-30 |
| Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed ParticipantsNCT02166047results2020-09-02Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Level at Week 24Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Vesatolimod, Placebo | Chronic Hepatitis B | 162 | 2016-05-11actual | — | 2020-10-14 |
| Selonsertib in Adults With Pulmonary Arterial HypertensionNCT02234141results2019-04-10Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Selonsertib | Pulmonary Arterial Hypertension | 151 | Apr 2016actual | — | 2019-04-10 |
| Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionNCT02480712results2017-06-01Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 107 | 2016-04-29actual | — | 2018-11-16 |
| Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionNCT02044822results2017-05-11Overall Response RateOpen-label · Treatment | Phase 2 | Terminated | Drug: Idelalisib, Rituximab | B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | 102 | 2016-04-27actual | — | 2018-11-19 |
| Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal AdenocarcinomaNCT02468557results2021-03-22Single-agent IDL: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: Idelalisib, Nab-paclitaxel, mFOLFOX6 | Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma | 16 | 2016-04-27actual | — | 2021-04-02 |
| Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic FunctionNCT02412098results2019-07-29PK (Pharmacokinetic) Parameter: AUCinf of EleclazineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Eleclazine | Long QT Syndrome | 49 | 2016-04-22actual | — | 2019-07-29 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell DiseaseNCT02301936results2017-05-25Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C Virus Infection | 10 | 2016-04-18actual | — | 2018-11-19 |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaNCT02258529results2017-05-18Overall Response RateOpen-label · Treatment | Phase 2 | Terminated | Drug: Idelalisib · Biological: Rituximab | Follicular Lymphoma, Small Lymphocytic Lymphoma | 10 | 2016-04-12actual | — | 2019-05-14 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV InfectionNCT02472886results2017-05-10Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Hepatitis C Virus Infection | 153 | 2016-03-30actual | — | 2018-11-16 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation SettingNCT02350569results2017-05-05Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C Virus Infection | 17 | 2016-03-28actual | — | 2018-11-19 |
| Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenNCT02536313results2017-09-14Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Treatment (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: SOF/VEL/VOX, RBV | Hepatitis C Virus Infection | 49 | 2016-03-28actual | — | 2019-02-25 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV InfectionNCT02251717results2017-11-17Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C Virus Infection | 114 | 2016-03-24actual | — | 2018-11-19 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV InfectionNCT02346721results2017-05-03Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL | Hepatitis C Virus Infection | 111 | 2016-03-23actual | — | 2018-11-16 |
| Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl EstradiolNCT02533427results2020-09-02Pharmacokinetic (PK) Parameter: AUCtau of NorelgestrominOpen-label · Treatment | Phase 1 | Completed | Drug: SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol | HCV Infection | 15 | 2016-03-18actual | — | 2020-09-02 |
| Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV InfectionNCT02202980results2017-11-17Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV, SOF/VEL, VOX | Chronic Hepatitis C | 273 | 2016-03-16actual | — | 2018-11-16 |
| Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentNCT02397707results2020-03-20Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClastNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Voxilaprevir | HCV Infection | 33 | 2016-03-04actual | — | 2020-04-09 |
| Study to Evaluate the Effects of MBX-8025 in Patients With HoFHNCT02472535LDL-COpen-label · Treatment | Phase 2 | Completed | Other: Run-In Period: Placebo · Drug: MBX-8025 50 mg (Dose Escalation Period 1), MBX-8025 50 mg or 100 mg (Dose Escalation Period 2), MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | Homozygous Familial Hypercholesterolemia | 13 | Feb 2016actual | — | 2016-03-09 |
| Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)NCT01769196results2017-04-13Progression Free SurvivalRandomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The Study was terminated due to lack of efficacy. | Drug: Simtuzumab, Simtuzumab placebo | Idiopathic Pulmonary Fibrosis | 544 | 2016-02-23actual | — | 2017-05-30 |
| Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)NCT01759511results2017-04-04Overall Safety Profile of SimtuzumabOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The Study was terminated due to lack of efficacy. | Drug: Simtuzumab | Idiopathic Pulmonary Fibrosis | 34 | 2016-02-19actual | — | 2017-04-04 |
| Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on TreatmentNCT02174276results2019-06-04Mean Change in Serum HBsAg From Baseline to Week 24Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Tenofovir disoproxil fumarate · Biological: GS-4774 | Chronic Hepatitis B | 195 | 2016-02-17actual | — | 2019-06-04 |
| Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionNCT02378935results2017-12-08Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: VOX, SOF/VEL, RBV | Hepatitis C Virus Infection | 205 | 2016-02-01actual | — | 2020-03-06 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-InfectionNCT02457611results2017-02-28Percentage of Participants With Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C Infection With HIV Co-Infection | 26 | Jan 2016actual | — | 2018-11-16 |
| Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected AdultsNCT02246998results2018-01-03Actual Glomerular Filtration Rate (aGFR) Using Iohexol Plasma Clearance (CLiohexol) at Week 24Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: STB, TVD, ATR, RTV, ATV, ABC/3TC, Iohexol | HIV-1 Infection | 72 | 2016-01-20actual | — | 2018-01-03 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 InfectionNCT02413593results2017-02-14Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV | Hepatitis C Virus Infection | 111 | Dec 2015actual | — | 2018-11-16 |
| Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal FunctionNCT02441829Plasma pharmacokinetics (PK) profiles of eleclazine and its metabolite GS-623134: AUC_0-inf and CmaxNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Eleclazine | Long QT Syndrome | 55 | Dec 2015actual | — | 2015-12-22 |
| Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic FunctionNCT02509624results2021-01-27Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Selonsertib | Diabetic Kidney Disease | 52 | 2015-12-15actual | — | 2021-01-27 |
| Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United StatesNCT00936715results2017-06-02Number of Participants Who Had Access to, and Received the InterventionOpen-label · Treatment | Phase 2 | Completed | Drug: FTC/TDF | Chronic Hepatitis B | 24 | Nov 2015actual | — | 2017-06-02 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment StudyNCT01987453results2017-01-10Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV | HCV Infection | 100 | Nov 2015actual | — | 2018-11-19 |
| Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT02397694results2018-03-27Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF | HIV-1 Infection | 98 | 2015-11-30actual | — | 2020-04-07 |
| Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e AntigenNCT01940471results2017-03-30Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: TAF, TDF, TAF Placebo, TDF Placebo | HBeAg-positive Chronic Hepatitis B | 875 | 2015-11-16actual | — | 2023-10-10 |
| Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)NCT02247934observationalList Primary Sclerosing Cholangitis (PSC) Symptoms for inclusion in patient questionnaire | — | Completed | — | Primary Sclerosing Cholangitis | 26 | Oct 2015actual | — | 2016-02-09 |
| Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in AdolescentsNCT01721109results2017-04-10For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVGOpen-label · Treatment | Phase 2/3 | Completed | Drug: EVG/COBI/FTC/TDF | Acquired Immunodeficiency Syndrome, HIV Infections | 50 | 2015-10-22actual | — | 2018-08-17 |
| Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e AntigenNCT01940341results2017-03-30Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mLRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: TAF, TDF, TAF Placebo, TDF Placebo | HBeAg-negative Chronic Hepatitis B | 426 | 2015-09-30actual | — | 2023-09-25 |
| Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV InfectionNCT02074514results2016-10-25Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Sofosbuvir, RBV | Chronic HCV Infection | 117 | Sep 2015actual | — | 2016-10-25 |
| Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV InfectionNCT02201953results2016-10-26Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL, SOF, RBV | Hepatitis C Virus Infection | 558 | Sep 2015actual | — | 2018-11-16 |
| Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult SubjectsNCT02876796Change in fractional DNL (% new palmitate)Randomized · Double-masked | Phase 1 | Completed | Drug: GS-0976, Placebo · Other: 1-13C acetate, Fructose solution | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | 30 | Sep 2015actual | — | 2016-08-24 |
| Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal ImpairmentNCT02402452results2020-03-20Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClastNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Voxilaprevir | HCV Infection | 20 | 2015-09-28actual | — | 2020-03-20 |
| Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV InfectionNCT02378961results2017-09-15Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: VOX, SOF/VEL | Hepatitis C Virus Infection | 128 | 2015-09-21actual | — | 2020-03-03 |
| A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLNCT01203930results2017-05-22Overall Response Rate (ORR)Open-label · Treatment | Phase 2 | Terminated | Drug: Idelalisib, Rituximab | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 105 | Aug 2015actual | — | 2018-11-16 |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaNCT01306643results2016-12-21Overall Safety of IdelalisibOpen-label · Treatment | Phase 1/2 | Completed | Drug: Idelalisib | Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma | 18 | Aug 2015actual | — | 2018-11-19 |
| A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal CancerNCT01915472SafetyRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: No participants enrolled | Drug: IMMU 130 | Metastatic Colorectal Cancer | 0 | Aug 2015actual | — | 2021-08-19 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding DisordersNCT02120300results2016-12-06Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, SOF, RBV | Chronic HCV Infection | 122 | Aug 2015actual | — | 2016-12-06 |
| Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B CirrhosisNCT02201901results2016-12-14Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL, RBV | Hepatitis C Virus Infection | 268 | Aug 2015actual | — | 2018-11-15 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV InfectionNCT02219685results2016-11-30Change From Baseline in Magnetic Resonance Spectroscopy (MRS) Metabolic Ratio at 4 Weeks After Discontinuation of Therapy: NAA + NAAGRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: LDV/SOF, Placebo | Hepatitis C Virus Infection | 40 | Aug 2015actual | — | 2018-11-16 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaNCT02258555Occurrence of adverse events (AEs) and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminated | Drug: GS-9901 | Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma | 7 | Aug 2015actual | — | 2015-10-19 |
| Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFNCT02121795results2016-11-30Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot AnalysisRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo | HIV-1 Infection | 668 | 2015-08-12actual | — | 2020-03-12 |
| Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV InfectionNCT02220998results2016-11-15Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF/VEL, SOF, RBV | Hepatitis C Virus Infection | 269 | Jul 2015actual | — | 2018-11-15 |
| Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsNCT01968551results2016-11-01Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen | HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome | 158 | 2015-07-21actual | — | 2018-11-16 |
| Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal FunctionNCT02400307results2019-10-11Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Bictegravir | HIV | 19 | 2015-07-06actual | — | 2019-10-11 |
| A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.NCT01510561Safety (change in hematology and chemistry laboratory values from baseline)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: no subjects enrolled | Drug: 90Y-hPAM4, 90Y-hPAM4, 90Y-hPAM4 + gemcitabine | Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer | 0 | Jun 2015 | — | 2021-08-19 |
| Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With CirrhosisNCT02128542results2016-08-03Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of TherapyOpen-label · Treatment | Phase 4 | Completed | Drug: Sofosbuvir, RBV | Hepatitis C Virus Infection | 66 | Jun 2015actual | — | 2016-08-03 |
| Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionNCT02201940results2016-09-16Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: SOF/VEL, Placebo | Hepatitis C Virus Infection | 741 | Jun 2015actual | — | 2018-11-15 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver TransplantNCT02010255results2016-06-20Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV | Chronic HCV Infection | 334 | May 2015actual | — | 2018-11-19 |
| Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy AdultsNCT02365532Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide | Long QT Syndrome | 60 | May 2015actual | — | 2015-05-20 |
| Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsNCT01967940results2017-06-12Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV | HIV, HIV Infections, Acquired Immunodeficiency Syndrome | 55 | 2015-05-21actual | — | 2018-11-16 |
| Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid ArthritisNCT02176876Incidence of adverse events, changes in laboratory tests and vital signs from baseline, and development of immunogenicity after dosingRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: GS-5745, Placebo to match GS-5745 | Rheumatoid Arthritis | 18 | Apr 2015actual | — | 2015-06-29 |
| Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT01088048results2021-03-18Duration of Exposure to IDELANon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide | Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 241 | 2015-04-28actual | — | 2021-03-18 |
| Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic ImpairmentNCT02296853results2020-12-09Pharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAFNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: TAF | Hepatitis B Virus | 20 | 2015-04-17actual | — | 2020-12-09 |
| Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 InfectionNCT00445146results2016-04-25Percentage of Participants Experiencing Any Treatment-Emergent Study Dug-Related Adverse EventOpen-label · Treatment | Phase 2 | Completed | Drug: EVG, RTV, ARV regimen | HIV Infections | 192 | Mar 2015actual | — | 2016-04-25 |
| Phase I Study of Milatuzumab for Graft Versus Host DiseaseNCT01663766All patients administered any dose of study drug will be included in the evaluation of safetyOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled | Drug: milatuzumab | GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) | 12 | Mar 2015actual | — | 2021-08-19 |
| Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV InfectionNCT01826981results2016-09-16Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, SOF, RBV, Peg-IFN, GS-9669, VEL | Chronic Hepatitis C | 359 | Mar 2015actual | — | 2018-11-16 |
| Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsNCT01815736results2016-04-14Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI | HIV, HIV Infections | 1,443 | 2015-03-16actual | — | 2021-04-13 |
| Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)NCT01442038results2016-07-15Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without RevascularizationRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ranolazine, Placebo | Coronary Artery Disease, Angina Pectoris | 2,651 | Feb 2015actual | — | 2016-07-15 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and CirrhosisNCT02226549results2016-03-04Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, VDV, RBV | Hepatitis C Virus Infection | 47 | Feb 2015actual | — | 2018-11-16 |
| Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLNCT01659255results2021-01-28Percentage of Participants Experiencing Dose-Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Tirabrutinib | Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia | 90 | 2015-02-23actual | — | 2021-03-16 |
| Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenNCT01705574results2016-03-10Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot AlgorithmRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF | Acquired Immunodeficiency Syndrome, HIV Infections | 583 | 2015-02-09actual | — | 2019-09-20 |
| Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CFNCT01641822results2016-05-09Rate of Protocol-defined Exacerbations (PDE) From Baseline Through Week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: AZLI, Placebo to match AZLI, Tobramycin inhalation solution | Cystic Fibrosis | 107 | Jan 2015actual | — | 2016-05-09 |
| Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver DecompensationNCT01687257results2016-02-24Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: SOF, RBV | Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation | 50 | Jan 2015actual | — | 2016-09-16 |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesNCT01796470results2020-06-02Objective Response Rate (ORR)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to safety measures. | Drug: Entospletinib, Idelalisib | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma | 66 | Jan 2015actual | — | 2020-06-02 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver TransplantNCT01938430results2016-04-15Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV | Chronic HCV Infection | 339 | Jan 2015actual | — | 2018-11-16 |
| Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout PatientsNCT02063997The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg | Gout | 248 | Jan 2015actual | — | 2018-01-29 |
| Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsNCT02071082results2016-04-04Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mLNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: E/C/F/TAF | HIV, HBV | 79 | 2015-01-23actual | — | 2018-11-16 |
| Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected ParticipantsNCT02275065results2020-10-08Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNARandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Bictegravir, Placebo | HIV-1 Infection | 23 | 2015-01-23actual | — | 2020-11-09 |
| SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV InfectionNCT01962441results2016-02-05Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF, RBV, Peg-IFN | Hepatitis C | 601 | 2015-01-07actual | — | 2017-06-20 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative ColitisNCT01831427results2021-02-01Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Andecaliximab, Placebo to match Andecaliximab | Ulcerative Colitis | 74 | 2015-01-05actual | — | 2021-02-01 |
| Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal CancerNCT01270698SafetyNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: IMMU-130 | Metastatic Colorectal Cancer | 26 | Dec 2014actual | — | 2021-08-19 |
| A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic LeukemiaNCT01659047Progression-free survivalOpen-label · Treatment | Phase 2 | Withdrawn | Drug: GS-1101 | Chronic Lymphocytic Leukemia | 0 | Dec 2014 | — | 2012-09-07 |
| Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutNCT02252835Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL on Day 29 after treatment with arhalofenate 800 mg and febuxostat 80 mgRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Arhalofenate, Febuxostat, Arhalofenate, Febuxostat, Colchicine | Gout, Hyperuricemia | 32 | Dec 2014actual | — | 2015-04-17 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)NCT02242045results2021-03-19Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib ExposureOpen-label · Treatment | Phase 1 | Completed | Drug: Idelalisib | Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia), Marginal Zone Lymphoma | 6 | 2014-12-25actual | — | 2021-03-19 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionNCT02185794results2020-08-21Percentage of Participants Experiencing Treatment Emergent Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL | Hepatitis C Virus Infection | 101 | 2014-12-22actual | — | 2020-09-17 |
| Study of the Effect of GS-6615 in Subjects With LQT-3NCT01849003Changes in QTc intervals (Fridericia formula)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GS-6615 | Long QT Syndrome | 24 | Nov 2014actual | — | 2014-11-17 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infectionNCT02073656results2016-10-21Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Hepatitis C Virus, HIV | 335 | Nov 2014actual | — | 2018-11-16 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV InfectionNCT02081079results2016-01-14Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF | Chronic Genotype 4 HCV, Chronic Genotype 5 HCV | 85 | Nov 2014actual | — | 2018-11-19 |
| Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal AdenocarcinomaNCT01479465results2019-04-17Progression Free Survival (PFS)Randomized · Double-masked · Treatment | Phase 2 | Terminated | Biological: Simtuzumab · Drug: Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil | Colorectal Cancer | 266 | Oct 2014actual | — | 2019-04-17 |
| Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV StudiesNCT01625338results2015-11-09Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF, RBV, Peg-IFN | Chronic Hepatitis C | 534 | Oct 2014actual | — | 2015-11-09 |
| A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected SubjectsNCT01850212observationalFemoral Neck and Spine (L1-4) T-score | — | Completed | — | HIV Infections | 476 | Oct 2014actual | — | 2014-10-31 |
| Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy AdultsNCT02209987PK profile of GS-5745Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GS-5745 SC, GS-5745 IV | Ulcerative Colitis | 28 | Oct 2014actual | — | 2014-10-27 |
| Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)NCT02077465results2020-08-13Percentage of Participants Experiencing Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Andecaliximab, Placebo to match Andecaliximab | Chronic Obstructive Pulmonary Disease | 11 | 2014-10-27actual | — | 2020-09-09 |
| Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver FibrosisNCT01707472results2019-10-09Percentage of Participants Experiencing Treatment-Emergent Adverse EventsNon-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Simtuzumab | Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection | 18 | 2014-10-17actual | — | 2019-11-05 |
| Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsNCT01797445results2016-01-08Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo | HIV, HIV Infections | 872 | 2014-09-19actual | — | 2020-03-02 |
| Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis BNCT01943799results2019-11-01Change From Baseline in HBsAg at Week 24Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: GS-4774 · Drug: OAV Regimen | Chronic HBV Infection | 178 | 2014-09-09actual | — | 2019-11-01 |
| Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis BNCT01277601results2015-09-09Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF AloneRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: TDF, Peg-IFN | Chronic Hepatitis B | 751 | Aug 2014actual | — | 2016-08-26 |
| Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin LymphomaNCT01393106results2015-12-24Overall Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: Idelalisib | Hodgkin Lymphoma | 25 | Aug 2014actual | — | 2018-11-19 |
| Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV InfectionNCT01965535results2015-09-28Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV, Placebo to match LDV/SOF, Placebo to match RBV | HCV Infection | 155 | Aug 2014actual | — | 2018-11-16 |
| Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsNCT01780506results2016-01-08Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo | HIV, HIV Infections | 872 | 2014-08-26actual | — | 2018-11-19 |
| Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentNCT01818596results2016-02-18Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24Open-label · Treatment | Phase 3 | Completed | Drug: E/C/F/TAF | HIV, HIV Infections | 252 | 2014-07-31actual | — | 2020-03-02 |
| Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV InfectionNCT01975675results2015-06-26Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12), Treatment-naive, Noncirrhotic ParticipantsRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Chronic HCV Infection | 341 | Jun 2014actual | — | 2018-11-16 |
| Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal ImpairmentNCT02002767results2020-11-16Pharmacokinetic (PK) Parameter of Velpatasvir: AUClastNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Velpatasvir | Hepatitis C Virus | 19 | 2014-06-09actual | — | 2020-11-16 |
| Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisNCT01369498results2020-07-01Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis ScoreRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Simtuzumab, Ruxolitinib | Myelofibrosis | 54 | 2014-06-05actual | — | 2020-07-01 |
| Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-TransplantNCT01559844results2015-05-28Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12Open-label · Treatment | Phase 2 | Completed | Drug: Sofosbuvir, Ribavirin | Hepatitis C, Hepatocellular Carcinoma | 61 | May 2014actual | — | 2016-07-27 |
| Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionNCT01838590results2015-05-22Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF, RBV | Hepatitis C Virus | 103 | May 2014actual | — | 2015-05-22 |
| Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV InfectionNCT01858766results2016-09-15Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: SOF, VEL, RBV | Hepatitis C | 379 | May 2014actual | — | 2018-11-14 |
| Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV InfectionNCT01909804results2016-09-16Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: SOF, VEL, RBV | Hepatitis C | 323 | May 2014actual | — | 2018-11-15 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV InfectionNCT01924949results2015-05-29Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF | Hepatitis C | 5 | May 2014actual | — | 2018-11-19 |
| A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsNCT01783678results2015-04-30Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Sofosbuvir, RBV | Chronic Hepatitis C, Human Immunodeficiency Virus | 275 | Apr 2014actual | — | 2015-04-30 |
| Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV InfectionNCT01896193results2015-04-17Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF, RBV | Hepatitis C | 127 | Apr 2014actual | — | 2015-05-29 |
| Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV InfectionNCT01984294results2015-05-21Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV, GS-9669 | Chronic HCV Infection | 101 | Apr 2014actual | — | 2018-11-19 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCVNCT01701401results2015-03-27Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Chronic Hepatitis C Virus | 870 | Mar 2014actual | — | 2018-11-16 |
| A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With SclerodermaNCT01881529observationalSummarized the number and percentage of subjects with elevated LOXL2 levels | — | Completed | — | Limited Scleroderma, Diffuse Scleroderma | 29 | Mar 2014actual | — | 2014-04-17 |
| Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV InfectionNCT01910636results2015-03-24Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 3 | Completed | Drug: Sofosbuvir, RBV | Hepatitis C | 153 | Mar 2014actual | — | 2015-03-24 |
| Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial FibrillationNCT01522651results2020-11-06Atrial Fibrillation Burden (AFB) at BaselineRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo | Atrial Fibrillation | 134 | 2014-03-10actual | — | 2020-11-06 |
| Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic LeukemiaNCT01259713results2015-04-06Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: Liposomal amphotericin B, Placebo | Invasive Fungal Disease | 355 | Dec 2013actual | — | 2015-05-07 |
| Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in TaiwanNCT01334567No statistical analyses are planned. Listings will include subject enrollment, subject disposition and SAEs.Open-label · Treatment | Phase 2 | Completed | Drug: Tenofovir DF | Hepatitis B | 30 | Dec 2013actual | — | 2014-03-04 |
| Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver TransplantNCT01687270results2014-12-19Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: Sofosbuvir, RBV | Recurrent Chronic Hepatitis C Virus, Post Liver Transplant | 40 | Dec 2013actual | — | 2014-12-19 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)NCT01851330results2014-12-30Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Chronic Hepatitis C Virus | 647 | Dec 2013actual | — | 2018-11-16 |
| Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01475838results2015-01-26Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: PI, RTV, FTC/TDF, Stribild | Acquired Immunodeficiency Syndrome, HIV Infections | 438 | Nov 2013actual | — | 2016-06-08 |
| Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01495702results2015-01-26Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: NNRTI, FTC/TDF, Stribild | Acquired Immunodeficiency Syndrome, HIV Infections | 439 | Nov 2013actual | — | 2016-01-07 |
| A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus InfectionNCT01590654Assessment of adverse events in single and multiple oral doses of GS-9620Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620 | Hepatitis B | 51 | Nov 2013actual | — | 2013-12-20 |
| Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsNCT01667731results2014-11-21Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: SOF, RBV | Hepatitis C, Human Immunodeficiency Virus | 224 | Nov 2013actual | — | 2014-11-21 |
| Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionNCT01713283results2014-11-25Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: SOF, RBV | Hepatitis C Virus | 60 | Nov 2013actual | — | 2014-11-25 |
| Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV InfectionNCT01768286results2014-11-26Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: LDV/SOF, RBV | Chronic Hepatitis C Virus | 441 | Nov 2013actual | — | 2018-11-16 |
| A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy SubjectsNCT01847391Safety and tolerability of GS-6615Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: GS-6615, Placebo | Ischemic Heart Disease | 36 | Nov 2013actual | — | 2013-11-13 |
| Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3NCT01260350results2014-11-17Percentage of Participants Who Experienced Adverse EventsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: SOF, RBV, PEG, LDV, GS-9669, LDV/SOF | Chronic Hepatitis C Infection | 292 | Oct 2013actual | — | 2014-11-17 |
| Ranolazine Monotherapy in Subjects With Type 2 Diabetes MellitusNCT01472185results2014-10-15Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Ranolazine, Placebo · Behavioral: Diet, Exercise | Type 2 Diabetes Mellitus | 465 | Oct 2013actual | — | 2014-10-24 |
| A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic AdenocarcinomaNCT01472198Progression free survivalRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Simtuzumab, Gemcitabine, Placebo to match simtuzumab | Pancreatic Cancer | 250 | Oct 2013actual | — | 2015-03-10 |
| A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)NCT01539512results2014-10-16Progression-Free SurvivalRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Idelalisib, Rituximab, Placebo to match idelalisib | Chronic Lymphocytic Leukemia | 220 | Oct 2013actual | — | 2019-05-14 |
| Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV InfectionNCT01682720results2014-10-09Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: SOF, RBV, Placebo to match SOF, Placebo to match RBV | Hepatitis C | 421 | Oct 2013actual | — | 2014-10-09 |
| A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AloneNCT01555164results2014-09-23Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin · Behavioral: Diet, Exercise | Type 2 Diabetes Mellitus | 442 | Sep 2013actual | — | 2014-09-23 |
| A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis BNCT01590641Assessment of adverse events in single and multiple oral doses of GS-9620Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts | Hepatitis B, HBV | 49 | Sep 2013actual | — | 2013-11-14 |
| Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3NCT01808248results2014-09-12Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Open-label · Treatment | Phase 2 | Completed | Drug: SOF, PEG, RBV | Hepatitis C | 47 | Sep 2013actual | — | 2014-09-12 |
| A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.NCT01843127Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: Ranolazine, Placebo, Exenatide | Type 2 Diabetes Mellitus | 24 | Sep 2013actual | — | 2014-03-31 |
| Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes MellitusNCT01494987results2014-09-01Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ranolazine, Placebo, Glimepiride · Behavioral: Diet, Exercise | Type 2 Diabetes Mellitus | 431 | Aug 2013actual | — | 2014-11-18 |
| Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.NCT01565889results2014-10-01Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: SOF, EFV/FTC/TDF, EFV, ZDV/3TC, ATV, Ritonavir, FTC/TDF, DRV, RAL, PEG, RBV | Hepatitis C, HIV | 52 | Aug 2013actual | — | 2014-10-01 |
| A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy AdultsNCT01779505Safety of GS-4774 at various dosesRandomized · Open-label · Treatment | Phase 1 | Completed | Biological: GS-4774 | Healthy Volunteers | 60 | Aug 2013actual | — | 2014-01-08 |
| Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)NCT01797419Safety and tolerabilityRandomized · Quadruple-masked · Treatment | Phase 1 | Withdrawn | Drug: GS-5806, Placebo | Respiratory Syncytial Virus Infections | 0 | Aug 2013 | — | 2013-10-28 |
| A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentNCT01817985Pharmacokinetic parameters of GS-5816Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GS-5816 | Chronic Hepatitis C | 33 | Aug 2013actual | — | 2013-08-29 |
| A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 PharmacokineticsNCT01841489Pharmacokinetic parameters for GS-9973Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J | Chronic Lymphocytic Leukemia | 56 | Aug 2013actual | — | 2014-02-07 |
| Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic CancerNCT00603863safety will be evaluated based upon physical examinations, hematology and chemistry laboratory testing as well as toxicityNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: IMMU-107 (hPAM4) | Pancreatic Cancer | 80 | Jul 2013actual | — | 2021-08-16 |
| A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple MyelomaNCT01101594All patients administered any dose of study drug will be included in the evaluation of safetyOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated due to lack of efficacy | Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab) | Multiple Myeloma | 17 | Jul 2013actual | — | 2021-08-16 |
| Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 SubjectsNCT01726517results2014-11-17Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: LDV/SOF, RBV | Chronic Hepatitis C Virus | 100 | Jul 2013actual | — | 2018-11-16 |
| Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CFNCT01840735Peak Plasma Concentration (Cmax) of GS-5737Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: GS-5737, Placebo | Cystic Fibrosis | 8 | Jul 2013actual | — | 2014-08-12 |
| GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusNCT01356160To evaluate the antiviral efficacy of response guided therapy.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: GS-5885, GS-9451, ribavirin tablet, GS-9451 Placebo · Biological: peginterferon alfa-2a | Hepatitis C, Chronic | 351 | Jun 2013actual | — | 2014-02-03 |
| GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeNCT01384383Sustained virologic response (SVR)Randomized · Open-label · Treatment | Phase 2 | Terminated | Drug: GS-5885, GS-9451, RBV, PEG | Chronic Hepatitis C | 248 | Jun 2013actual | — | 2014-02-03 |
| Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)NCT01756482Change in viral load measurements.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: GS-5806, Placebo | Respiratory Syncytial Virus Infections | 140 | Jun 2013actual | — | 2015-08-21 |
| A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy SubjectsNCT01793649Area under the curve of MCC from Whole Lung CompartmentRandomized · Quadruple-masked · Treatment | Phase 1 | Terminated | Drug: GS-5737 | Cystic Fibrosis, Chronic Obstructive Pulmonary Disease | 7 | Jun 2013actual | — | 2014-03-20 |
| Aztreonam Lysine for Pseudomonas Infection Eradication StudyNCT01375049results2014-07-01Percentage of Participants With PA-negative Cultures at All Time Points After Cessation of Active Treatment (Evaluable Analysis Set)Open-label · Treatment | Phase 2 | Completed | Drug: Aztreonam for Inhalation Solution (AZLI) | Cystic Fibrosis | 105 | May 2013actual | — | 2014-07-17 |
| Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of AgeNCT01754428observationalDetermine the percentage of medically attended Respiratory Syncytial Virus- positive subjects hospitalized for Respiratory Syncytial Virus related symptoms | — | Completed | — | Respiratory Syncytial Virus Infections | 2,432 | May 2013actual | — | 2013-08-20 |
| Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis BronchiectasisNCT01314716results2014-04-16Change in QOL-B Respiratory Symptoms Score at Day 28Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: AZLI, Placebo | Bronchiectasis | 274 | Apr 2013actual | — | 2014-04-16 |
| Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower AirwaysNCT01404234results2014-05-01Percentage of Participants Who Discontinued Study Drug Due to Safety or Tolerability ReasonsOpen-label · Treatment | Phase 3 | Completed | Drug: AZLI | Cystic Fibrosis, Pseudomonas Aeruginosa | 61 | Apr 2013actual | — | 2014-05-29 |
| Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C InfectionNCT01435044Percentage of participants with sustained virologic response (SVR) 12 weeks after discontinuation of study drug (SVR12)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938 | Hepatitis C, Chronic | 239 | Apr 2013actual | — | 2014-02-06 |
| A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis BNCT01671787Change in serum hepatitis B virus (HBV) DNARandomized · Open-label · Treatment | Phase 1 | Completed | Drug: GS-7340, Tenofovir disoproxil fumarate | Chronic Hepatitis B | 51 | Apr 2013actual | — | 2018-10-23 |
| A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806NCT01801293Urine and fecal recovery of total [14C]-radioactivityOpen-label · Treatment | Phase 1 | Completed | Drug: GS-5806 | RSV Infection | 8 | Apr 2013actual | — | 2013-06-10 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLNCT00546793Safety/tolerabilityOpen-label · Treatment | Phase 1/2 | Completed | Biological: veltuzumab | NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Intermediate-Grade, Lymphoma, Large-Cell, Lymphoma, Low-Grade, Lymphoma, Mixed-Cell, Lymphoma, Small-Cell, Leukemia, Lymphocytic, Chronic, Leukemia, B-Cell, Chronic, Leukemia, Prolymphocytic, Leukemia, Small Lymphocytic, Lymphoma, Small Lymphocytic, Lymphoma, Lymphoplasmacytoid, CLL, Lymphoplasmacytoid Lymphoma, CLL, CLL, SLL | 32 | Mar 2013actual | — | 2021-08-16 |
| Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis BronchiectasisNCT01313624results2014-04-16Change in QOL-B Respiratory Symptoms Score at Day 28Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: AZLI, Placebo | Bronchiectasis | 266 | Mar 2013actual | — | 2014-04-16 |
| Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionNCT01371578Sustained Virologic Response (SVR)Open-label · Treatment | Phase 2 | Completed | Drug: GS-5885 tablet, GS-9451 tablet, ribavirin tablet · Biological: peginterferon alfa-2a | Hepatitis C, Chronic | 163 | Mar 2013actual | — | 2014-02-11 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV InfectionNCT01740791results2020-12-16Percentage of Participants Experiencing Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Velpatasvir, Placebo | Chronic Hepatitis C Virus | 103 | 2013-03-15actual | — | 2020-12-16 |
| Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal CancerNCT01273402Determine the number of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: A new study is being designed. No patients were enrolled. | Drug: TF2/IMP288 | Metastatic Colorectal Cancer | 0 | Feb 2013actual | — | 2021-08-16 |
| Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)NCT01604850results2014-05-01Percentage of Participants Achieving SVR12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: SOF, RBV, Placebo to match SOF, Placebo to match RBV | Chronic Hepatitis C | 202 | Feb 2013actual | — | 2014-05-28 |
| Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLLNCT00603668Safety of the anti-CD74 antibody will be evaluated based upon physical examinations, hematology and chemistry laboratory evaluations and toxicity eventsOpen-label · Treatment | Phase 1/2 | Completed | Biological: milatuzumab | Chronic Lymphocytic Lymphoma | 19 | Jan 2013actual | — | 2021-08-16 |
| A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CNCT01225380Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessationRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: GS-9190, GS-9256, Copegus®, GS-9190 placebo, GS-9256, Copegus®, GS-9190 placebo, GS-9256 placebo, Copegus® · Biological: Pegasys®, Pegasys®, Pegasys® | Chronic Hepatitis C Infection | 324 | Jan 2013actual | — | 2014-01-28 |
| A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CNCT01271790Sustained virologic responseRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Tegobuvir (GS-9190), GS-9451, Copegus®, GS-9451, Tegobuvir placebo, Copegus®, Tegobuvir placebo, GS-9451 placebo, Copegus® · Biological: Pegasys®, Pegasys®, Pegasys® | Hepatitis C, Chronic | 245 | Jan 2013actual | — | 2014-02-06 |
| Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentNCT01363011results2014-10-31Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: E/C/F/TDF, COBI, ATV, DRV, NRTI | Acquired Immunodeficiency Syndrome, HIV Infections | 106 | Jan 2013actual | — | 2016-05-02 |
| GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionNCT01434498Safety and TolerabilityRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet · Device: placebo matching tegobuvir capsule | Chronic Genotype 1a or 1b HCV Infection | 163 | Jan 2013actual | — | 2013-12-20 |
| GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionNCT01435226Safety and TolerabilityRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin | Hepatitis C, Chronic | 170 | Jan 2013actual | — | 2013-12-17 |
| Pilot Study of Simtuzumab in the Treatment of Liver FibrosisNCT01452308Incidence of adverse events on multiple, escalating IV doses of simtuzumabNon-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Simtuzumab | Liver Fibrosis | 20 | Jan 2013actual | — | 2014-02-03 |
| Phase 3 Study of Sofosbuvir and RibavirinNCT01497366results2014-04-02Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Sofosbuvir, PEG, RBV | Hepatitis C | 527 | Jan 2013actual | — | 2014-04-02 |
| D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsNCT01565850results2016-04-11Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo | Acquired Immunodeficiency Syndrome, HIV Infections | 153 | Jan 2013actual | — | 2016-04-11 |
| Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV InfectionNCT01641640results2014-05-08Percentage of Participants Achieving Sustained Virologic Response (SVR)12Open-label · Treatment | Phase 3 | Completed | Drug: Sofosbuvir, RBV, PEG | Chronic Hepatitis C | 328 | Jan 2013actual | — | 2014-05-08 |
| A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary FibrosisNCT01362231To characterize the safety, tolerability, and pharmacokinetics (PK) of GS-6624Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: GS-6624 | Idiopathic Pulmonary Fibrosis | 48 | Dec 2012actual | — | 2015-07-09 |
| A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis CNCT01591668Incidence of adverse events in single and multiple doses of GS-9620Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620 | Hepatitis C | 51 | Dec 2012actual | — | 2013-08-13 |
| Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01533259results2015-01-26Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12Open-label · Treatment | Phase 3 | Completed | Drug: Stribild | Acquired Immunodeficiency Syndrome, HIV Infections | 48 | Nov 2012actual | — | 2015-01-26 |
| Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take InterferonNCT01542788results2014-02-17Percentage of Participants Achieving SVR12Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: SOF, RBV, Placebo to match SOF, Placebo to match RBV | Chronic Hepatitis C | 278 | Nov 2012actual | — | 2014-05-19 |
| A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)NCT01334203The primary efficacy endpoint is the change from baseline in exercise treadmill duration in the peak ETT at week 12 or last visit.Randomized · Quadruple-masked · Treatment | Phase 4 | Withdrawn | Drug: Ranolazine | Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus | 0 | Oct 2012 | — | 2012-07-31 |
| GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionNCT01353248Sustained virologic response (SVR)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: GS-5885, Tegobuvir, GS-9451, ribavirin tablet, GS-5885 | Hepatitis C, Chronic | 141 | Oct 2012actual | — | 2013-12-20 |
| Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable AnginaNCT01425359results2014-11-04Average Weekly Angina Frequency Over the Last 6 Weeks of TreatmentRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Ranolazine, Ranolazine placebo | Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus | 949 | Oct 2012actual | — | 2014-11-04 |
| Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in IndiaNCT01772121observationalVariation in the IL28B rs12979860 SNP | — | Completed | — | Hepatitis B, Hepatitis C | 1,000 | Oct 2012actual | — | 2015-07-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19